[go: up one dir, main page]

WO2018126499A1 - 网织红细胞模拟粒子、血小板模拟粒子制备方法及质控物 - Google Patents

网织红细胞模拟粒子、血小板模拟粒子制备方法及质控物 Download PDF

Info

Publication number
WO2018126499A1
WO2018126499A1 PCT/CN2017/071755 CN2017071755W WO2018126499A1 WO 2018126499 A1 WO2018126499 A1 WO 2018126499A1 CN 2017071755 W CN2017071755 W CN 2017071755W WO 2018126499 A1 WO2018126499 A1 WO 2018126499A1
Authority
WO
WIPO (PCT)
Prior art keywords
red blood
particles
blood cells
fluorescent dye
platelet
Prior art date
Application number
PCT/CN2017/071755
Other languages
English (en)
French (fr)
Inventor
刘博�
谢键
陈庚文
宋瑞霞
Original Assignee
深圳迈瑞生物医疗电子股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 深圳迈瑞生物医疗电子股份有限公司 filed Critical 深圳迈瑞生物医疗电子股份有限公司
Priority to US16/476,104 priority Critical patent/US20190352609A1/en
Priority to CN202110162478.4A priority patent/CN112986589B/zh
Priority to CN201780081863.8A priority patent/CN110140051B/zh
Publication of WO2018126499A1 publication Critical patent/WO2018126499A1/zh

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0641—Erythrocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0644—Platelets; Megakaryocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/34—Purifying; Cleaning
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/1012—Calibrating particle analysers; References therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
    • G01N35/00584—Control arrangements for automatic analysers
    • G01N35/00594—Quality control, including calibration or testing of components of the analyser
    • G01N35/00613—Quality control
    • G01N35/00623—Quality control of instruments
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N2001/2893—Preparing calibration standards
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
    • G01N2001/302—Stain compositions
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/40—Concentrating samples
    • G01N1/4077—Concentrating samples by other techniques involving separation of suspended solids
    • G01N2001/4088—Concentrating samples by other techniques involving separation of suspended solids filtration
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N2015/1006—Investigating individual particles for cytology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/1012—Calibrating particle analysers; References therefor
    • G01N2015/1014—Constitution of reference particles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N2015/1024—Counting particles by non-optical means
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N2015/1028—Sorting particles

Definitions

  • the present application relates to the field of blood quality control, and in particular to a method for preparing reticulocyte simulated particles, a method for preparing platelet simulated particles, and a control comprising the prepared reticulocyte simulated particles and platelet mimic particles.
  • Reticulocytes are red blood cells that are not yet fully mature. They are important indicators reflecting the hematopoietic function of bone marrow and the efficacy of anemia and related diseases. They are important for the diagnosis and treatment of blood diseases. Reticulocyte-related parameters are an important piece of information provided by medium and high-end blood cell analyzers.
  • a blood control is a liquid containing single or multi-component blood cells or blood cell mimics that has the same detectable properties as blood for routine monitoring of the accuracy and precision of the blood analyzer.
  • Reticulocyte simulated particles and platelet mimetic particles are blood cell mimics that mimic reticulocytes and platelets, respectively, in blood controls.
  • Method 1 The cell membrane of red blood cells is expanded by the change of osmotic pressure to produce small pores, and then the nucleic acid is injected into the cells to simulate the morphology of reticulocytes; the preparation method requires the process. High, the process operation is difficult, the mass production efficiency is low, and the cells have undergone expansion and contraction, and the film strength is lowered.
  • Method 2 enriching and purifying anemia animals, such as pigs, reticulocytes in the blood, and fixing agents to achieve particle stability. The preparation method is difficult to refine red blood cells, high cost of animal blood raw materials, and particle volume parameters. It is not possible to effectively simulate the distribution of human reticulocytes.
  • Method 3 By oxidizing exogenous nucleic acid, the surface of the aldehyde group is cross-linked with the surface of human erythrocyte membrane to realize the simulation of particle fluorescence signal.
  • the process steps of the method are too many, the reaction conditions are complicated and uncontrollable, and the practicability and controllability of the process are reduced.
  • Method 1 Using human platelet as a raw material, the platelet stability is enhanced by using polyethylene glycol (abbreviation PEG), which is easy to activate and initiate aggregation effect, leading to failure of quality control products, and commercial source of human platelet is expensive.
  • Method 2 Using low-cost goat red blood cells as raw materials to prepare platelet mimic particles, this method can reduce the aggregation effect of human platelets, but this method needs to shrink the goat red blood cells to adjust the volume to prepare platelet mimic particles. The human platelet volume distribution cannot be effectively simulated, and the collapsed sheep red blood cells have a tendency to recover from deformation in the isotonic preservation solution.
  • Method 3 Use a mountain with different red blood cell volume characteristics Mixed with sheep blood, simulating human platelet volume distribution, but its processing technology is too complicated, and because the platelet particles after fixation have anti-solubility effect on hemolytic agent, when the control substance containing platelets and white blood cells is used for detection, the method is prepared.
  • the platelet mimics particles, which can cause a false increase in white blood cell counts, affecting the accuracy of quality control.
  • Method 4 By weakly fixing the animal red blood cells, satisfying the solvable demand under the action of the hemolytic agent, and then down-regulating the volume to the volume by different osmotic pressure environments, mixing red blood cells of different volume sizes to achieve approximate human platelet volume distribution, but the process practicality and Control is still a big challenge.
  • the purpose of the present application is to provide a novel method for preparing reticulocyte simulated particles, platelet mimetic particles, and a control containing the prepared reticulocyte simulated particles and platelet mimetic particles.
  • One aspect of the present application discloses a method for preparing reticulocyte-simulating particles, comprising dyeing a mammalian seedless red blood cell using a N-hydroxysuccinimide-activated protein fluorescent dye having a carboxyl group, and no mammalian
  • the nucleated red blood cells are fixed and processed into reticulocyte simulated particles; wherein the fixation treatment can be performed before or after the staining, the size of the mammalian seedless red blood cells is 60-120 fL, and the mammalian seedless red blood cells are preferably human red blood cells, Rabbit red blood cells, bovine red blood cells, pig red blood cells, horse red blood cells or guinea pig red blood cells.
  • the key of the present application is to stain the mammalian seedless red blood cells with a volume of 60-120 fL by using N-hydroxysuccinimide activated protein fluorescent dye; wherein, the size of the mammalian seedless red blood cells is limited. It is 60-120fL, which makes the prepared simulated particles can effectively simulate the fluorescence and volume properties of reticulocytes. Moreover, the simulated particles obtained by dyeing N-hydroxysuccinimide-activated protein fluorescent dyes of the present application have membrane properties similar to those of reticulocytes, and can satisfy the quality control requirements of hemolysis and non-hemolytic detection channels.
  • N-hydroxysuccinimide-activated protein fluorescent dye refers to N-hydroxysuccinimide of the carboxyl group of the protein fluorescent dye, which can stably bind the protein fluorescent dye to the surface of the mammalian seedless red blood cell membrane, thereby ensuring The stability of the protein fluorescent dye linkage in the simulated particles.
  • mammalian seedless reds with a size of 60-120 fL
  • the cells mainly include human red blood cells, rabbit red blood cells, bovine red blood cells, pig red blood cells, horse red blood cells and guinea pig red blood cells, etc., which can be used for preparing the reticulocyte simulated particles of the present application; it can be understood that the reticulocyte simulated particles of the present application, As long as the volume of the raw material-free red blood cells is 60-120 fL, it can be used in the present application, and is not limited to human red blood cells, rabbit red blood cells, bovine red blood cells, pig red blood cells, horse red blood cells, and guinea pig red blood cells.
  • the immobilization treatment is a weak fixation treatment, that is, while fixing the cells, it is capable of maintaining a certain cell activity, so that it can be stably stabilized for a long period of time, and can be dissolved by the action of the hemolytic agent.
  • the preparation method of the present application can obtain the reticulocyte simulated particles simply and effectively, and further can be further spheroidized on the basis of the reticulocyte simulated particles prepared in the present application to meet different use requirements.
  • the specific steps of the spheronization treatment can be integrated into the preparation method of the present application, and are not specifically limited herein.
  • the N-hydroxysuccinimide-activated protein fluorescent dye having a carboxyl group is used to dye mammalian seedless red blood cells, including the following steps.
  • the protein fluorescent dye has an activated carboxyl group, and the carboxyl group is activated by N-hydroxysuccinimide;
  • the N-hydroxysuccinimide-activated protein fluorescent dye is incubated with mammalian seedless red blood cells, and the mammalian seedless red blood cells are stained to obtain stained red blood cells.
  • the method of preparation of the present application further comprises washing the stained and fixed cells.
  • the purpose of the wash is to remove excess or bound unstable protein fluorescent dyes and fixatives to avoid affecting subsequent steps or other components of the fusion control, using conventional buffers such as citric acid and A mixed solution of sodium citrate or a mixed solution of citric acid, sodium citrate and sodium chloride is not specifically limited herein.
  • the N-hydroxysuccinimide activated protein fluorescent dye having a carboxyl group is a structure represented by the general formula 1,
  • R is a protein fluorescent dye
  • n is an integer from 1 to 4, and the value of n depends on the number of carboxyl groups of the protein fluorescent dye.
  • the protein fluorescent dye is at least one of the structures represented by the general formula II, the general formula III, the general formula IV and the general formula 5.
  • m is 0, 1 , 2 or 3
  • R 1 and R 2 are each independently selected from a sulfonic acid group, a halogen atom or a hydrogen atom;
  • R 3 and R 4 are each independently selected from an alkyl group or a carboxyl group-containing alkyl group, and at least one of R 3 and R 4 is a carboxyl group-containing alkyl group;
  • R 5 and R 6 are each independently selected from a sulfonic acid group, a halogen atom, an alkyl group or a hydrogen atom.
  • the protein fluorescent dye is at least one of fluorescent dyes A-H,
  • the structural formula of fluorescent dye B is The structural formula of fluorescent dye C is The structural formula of fluorescent dye D is The structural formula of fluorescent dye E is The structural formula of fluorescent dye F is
  • the structural formula of the fluorescent dye G is The structural formula of the fluorescent dye H is
  • the fixing agent used in the fixing treatment is at least one of a heavy metal salt, formaldehyde, pyruvic aldehyde, glutaraldehyde and paraformaldehyde;
  • the reaction concentration of formaldehyde, pyruvic aldehyde, glutaraldehyde or paraformaldehyde is from 0.005% to 1% by volume.
  • the heavy metal salt is a dichromate, more preferably potassium dichromate or dichromic acid.
  • the preparation method of the present application further comprises spheronizing the mammalian seedless red blood cells.
  • Another aspect of the present application discloses a reticulocyte simulated particle prepared by the preparation method of the present application.
  • the other side of the present application discloses a method for preparing platelet mimetic particles, comprising dyeing a mammalian seedless red blood cell with a nucleic acid fluorescent dye having a carboxyl group activated by N-hydroxysuccinimide, and treating the mammalian seedless red blood cells
  • the immobilization treatment is carried out to prepare platelet mimic particles; the fixation treatment can be carried out before or after staining, the size of mammalian seedless red blood cells is 2-25 fL, and the mammalian seedless red blood cells are preferably goat-derived red blood cells or sheep red blood cells.
  • the key of the present application is to stain the mammalian seedless red blood cells with a volume of 2-25 fL by using N-hydroxysuccinimide activated protein fluorescent dye; wherein the size of the mammalian seedless red blood cells is limited. It is 2-25fL, which makes the prepared simulated particles can effectively simulate the fluorescence and volume properties of platelets. Moreover, the simulated particles obtained by dyeing N-hydroxysuccinimide-activated protein fluorescent dyes of the present application have membrane properties similar to those of platelets, and can satisfy the quality control requirements of hemolysis and non-hemolytic detection channels.
  • the platelet mimetic particle preparation method and the reticulocyte simulated particle preparation method of the present application are the same in that the same N-hydroxysuccinimide-activated protein fluorescent dye is used for dyeing, and the key difference between the two is that Mammalian red blood cell raw materials of different sizes are used. It has been confirmed by the study of the present application that mammalian seedless red blood cells having a volume of 60-120 fL can simulate reticulocytes using the preparation method of the present application, and mammalian seedless red blood cells having a size of 2-25 fL can simulate platelets.
  • mammalian seedless red blood cells having a volume of 2-25 fL mainly include goat-derived red blood cells or sheep red blood cells, both of which can be used to prepare platelet mimetic particles of the present application; it is understood that the present application
  • the platelet-simulating particles can be used in the present application as long as the volume of the raw material red blood cells satisfies 2-25 fL, and is not limited to goat-derived red blood cells or sheep red blood cells.
  • the preparation method of the present application can obtain platelet mimetic particles simply and effectively. Based on the platelet mimic particles prepared in the present application, it can be further spheroidized to meet different use requirements.
  • the specific steps of the spheronization treatment can be integrated into the preparation method of the present application, and are not specifically limited herein.
  • platelet mimetic particles prepared by the preparation method of the present application are disclosed, and the platelet mimetic particles contain reticulated platelet mimetic particles.
  • Yet another aspect of the present application discloses a quality control or calibrant for a blood analyzer comprising the reticulocyte simulated particles of the present application and/or platelet mimetic particles of the present application.
  • control or calibrator further comprises at least one of leukocyte mimetic particles, red blood cell mimic particles and nucleated red blood cell mimic particles.
  • the concentration of components such as erythrocyte simulated particles, platelet mimic particles, white blood cells or white blood cell mimic particles, red blood cells or red blood cell mimic particles can be adjusted according to different use requirements.
  • the low value, the median value, the high value control substance or the calibrator are prepared, and are not specifically limited herein.
  • a cell mimetic particle for a blood analyzer is disclosed, the cell mimetic particle being a mammalian seedless red blood cell surface-crosslinked with at least one protein fluorescent dye molecule.
  • the key point of the present application is to use the mammalian seedless red blood cell surface cross-linking dye to simulate the fluorescence and volume properties of other blood cells, and to prepare blood cell mimic particles for quality control of the blood analyzer.
  • a mammalian seedless red blood cell cross-linked protein fluorescent dye molecule having a volume of 60-120 fL is specifically pointed out, and the obtained cell mimicking particles have a scattergram fluorescence and a volume direction which coincide with the reticulocyte. Distribution, can simulate reticulocytes. Based on this, the present application proposes a method for preparing reticulated red blood cell mimic particles.
  • the mammalian seedless red blood cells having a volume of 60-120 fL are human red blood cells, rabbit red blood cells, bovine red blood cells, pig red blood cells, horse red blood cells or guinea pig red blood cells.
  • a mammalian seedless erythrocyte cross-linked protein fluorescent dye molecule having a size of 2-25 fL is indicated, and the obtained cell mimicking particles have a scattergram fluorescence and volume direction which coincide with reticulated platelets and The distribution of platelets can mimic platelets with reticulated platelets. Therefore, the present application proposes a method of preparing platelet mimetic particles.
  • the mammalian seedless red blood cells having a volume of 2-25 fL are goat-derived red blood cells or sheep red blood cells.
  • the above two preferred schemes utilize the difference in cross-linking reaction to form The difference in particle fluorescence intensity is obtained to obtain reticulocyte simulated particles, respectively, and platelet mimic particles with reticulated platelet mimic particles.
  • inventive idea of the present application is to simulate the fluorescence and volume properties of other blood cells by using mammalian seedless red blood cell surface cross-linking dye. Under this guidance, other blood cells for blood analyzers can be simulated, not limited to nets. Erythrocyte simulated particles and platelet mimic particles with reticulated platelet mimetic particles.
  • the mammalian seedless erythrocyte cross-linking protein fluorescent dye molecule of the present application preferably, by using a protein fluorescent dye molecule having an activated carboxyl group, crosslinks the activated amino group on the cell surface of the mammalian seedless red blood cell, That is, the amino group and the carboxyl group are crosslinked by N-hydroxysuccinimide.
  • the cell mimicking particles for the blood analyzer of the present application which employs the protein fluorescent dye, are preferably at least one of the structures represented by the general formula II, the general formula III, the general formula IV, and the general formula 5. More preferably, the mammalian seedless red blood cells used in the present application are also subjected to a spheroidization treatment.
  • the method for preparing reticulocyte simulated particles and platelet mimic particles of the present application uses N-hydroxysuccinimide-activated protein fluorescent dye to stain mammalian seedless red blood cells of different sizes, thereby obtaining reticulocyte simulated particles and Platelet mimics particles.
  • the simulated particles prepared in the present application have a scatter plot of fluorescence and volume direction close to the distribution of fresh blood reticulocytes, reticulated platelets and platelets, which have good stability and do not interfere with white blood cells and nucleated red blood cell channels. Counting and classification.
  • the preparation method of the present application is simple and convenient for processing, and provides a new preparation method and route for reticulocyte simulated particles and platelet mimic particles.
  • control material containing the reticulocyte simulated particles and the platelet mimetic particles of the present application can also be mixed with the leukocyte mimic particles, the nucleated red blood cell mimic particles and the red blood cell mimic particles to prepare a fusion quality control substance, and the single product is completed for blood analysis.
  • FIG. 1 is a flow chart of preparing simulated particles in an embodiment of the present application
  • FIG. 2 is a reticulocyte simulated particle prepared by the fluorescent dye A and a platelet-simulated particle containing reticulated platelets in the RET channel of the Mindray BC-6 series blood cell analyzer in the embodiment of the present application.
  • the detected scattergram, the abscissa indicates the fluorescence intensity, and the ordinate indicates the forward scattered light intensity;
  • FIG. 3 is a preparation of reticulocyte simulated particles prepared by fluorescent dye A and platelet-simulated particles containing reticulated platelets in the examples of the present application, after adding leukocyte mimic particles, nucleated red blood cell mimic particles, red blood cell mimic particles, and preservation solution.
  • the scatter plot of the low, medium, and high levels of the fusion control wherein the abscissa of the RET channel represents the fluorescence intensity, the ordinate represents the intensity of the forward scattered light, the abscissa of the Diff channel represents the intensity of the side scattered light, and the ordinate represents the intensity of the fluorescence.
  • the abscissa of the Baso channel represents the intensity of the side scattered light
  • the ordinate represents the intensity of the forward scattered light
  • the abscissa of the NRBC channel represents the intensity of the fluorescence
  • the ordinate represents the intensity of the forward scattered light
  • RET channel abscissa indicates fluorescence intensity
  • ordinate indicates forward scattered light.
  • Diff channel abscissa indicates side scattered light intensity
  • ordinate indicates fluorescence intensity
  • Baso channel abscissa indicates side scattered light intensity
  • ordinate indicates forward scattered light intensity
  • NRBC channel abscissa indicates fluorescence intensity
  • ordinate indicates Forward scattered light intensity
  • FIG. 5 is a scatter plot of reticulocyte simulated particles prepared by fluorescent dye B and platelet mimic particles containing reticulated platelets in the RET channel of Mindray BC-6 series blood cell analyzer, and the abscissa indicates fluorescence intensity. The ordinate indicates the forward scattered light intensity;
  • reticulocyte simulated particles prepared by fluorescent dye B and platelet-simulated particles containing reticulated platelets in the examples of the present application, after adding leukocyte mimic particles, nucleated red blood cell mimic particles, red blood cell mimic particles, and preservation solution.
  • a scatter plot of the value of the fusion control where the abscissa of the RET channel represents the fluorescence intensity, the ordinate represents the intensity of the forward scattered light, the abscissa of the Diff channel represents the intensity of the side scattered light, the ordinate represents the intensity of the fluorescence, and the abscissa of the Baso channel Indicates the intensity of the side scattered light, the ordinate represents the intensity of the forward scattered light, the abscissa of the NRBC channel represents the intensity of the fluorescence, and the ordinate represents the intensity of the forward scattered light;
  • Figure 7 is a scatter plot of reticulocyte simulated particles prepared by fluorescent dye C and platelet mimic particles containing reticulated platelets in the RET channel of Mindray BC-6 series blood cell analyzer, and the abscissa indicates fluorescence intensity. The ordinate indicates the forward scattered light intensity;
  • reticulocyte simulated particles prepared by fluorescent dye C and platelet-simulated particles containing reticulated platelets in the examples of the present application, after adding leukocyte mimic particles, nucleated red blood cell mimic particles, red blood cell mimic particles, and preservation solution.
  • a scatter plot of the value of the fusion control where the abscissa of the RET channel represents the fluorescence intensity, the ordinate represents the intensity of the forward scattered light, the abscissa of the Diff channel represents the intensity of the side scattered light, the ordinate represents the intensity of the fluorescence, and the abscissa of the Baso channel Indicates the intensity of the side scattered light, the ordinate represents the intensity of the forward scattered light, the abscissa of the NRBC channel represents the intensity of the fluorescence, and the ordinate represents the intensity of the forward scattered light;
  • Figure 9 is a reticulocyte simulated particle prepared by fluorescent dye D and platelet mimic particles containing reticulated platelets in the RET channel of Mindray BC-6 series blood cell analyzer in the examples of the present application.
  • the detected scattergram, the abscissa indicates the fluorescence intensity, and the ordinate indicates the forward scattered light intensity;
  • reticulocyte simulated particles prepared by fluorescent dye D and platelet-simulated particles containing reticulated platelets in the examples of the present application, after adding leukocyte mimic particles, nucleated red blood cell mimic particles, red blood cell mimic particles, and preservation solution.
  • a scatter plot of the value of the fusion control where the abscissa of the RET channel represents the fluorescence intensity, the ordinate represents the intensity of the forward scattered light, the abscissa of the Diff channel represents the intensity of the side scattered light, the ordinate represents the intensity of the fluorescence, and the abscissa of the Baso channel Indicates the intensity of the side scattered light, the ordinate represents the intensity of the forward scattered light, the abscissa of the NRBC channel represents the intensity of the fluorescence, and the ordinate represents the intensity of the forward scattered light;
  • Figure 11 is a scatter plot of reticulocyte simulated particles prepared by fluorescent dye E and platelet-simulated particles containing reticulated platelets in the RET channel of Mindray BC-6 series blood cell analyzer, and the abscissa indicates fluorescence intensity. The ordinate indicates the forward scattered light intensity;
  • reticulocyte simulated particles prepared by fluorescent dye E and platelet-simulated particles containing reticulated platelets in the examples of the present application, after adding leukocyte mimic particles, nucleated red blood cell mimic particles, red blood cell mimic particles, and preservation solution.
  • a scatter plot of the value of the fusion control where the abscissa of the RET channel represents the fluorescence intensity, the ordinate represents the intensity of the forward scattered light, the abscissa of the Diff channel represents the intensity of the side scattered light, the ordinate represents the intensity of the fluorescence, and the abscissa of the Baso channel Indicates the intensity of the side scattered light, the ordinate represents the intensity of the forward scattered light, the abscissa of the NRBC channel represents the intensity of the fluorescence, and the ordinate represents the intensity of the forward scattered light;
  • Figure 13 is a scatter plot of reticulocyte simulated particles prepared by fluorescent dye F and platelet mimic particles containing reticulated platelets in the RET channel of Mindray BC-6 series blood cell analyzer, and the abscissa indicates fluorescence intensity. The ordinate indicates the forward scattered light intensity;
  • reticulocyte simulated particles prepared by fluorescent dye F and platelet-simulated particles containing reticulated platelets in the examples of the present application, after adding leukocyte mimic particles, nucleated red blood cell mimic particles, red blood cell mimic particles, and preservation solution.
  • a scatter plot of the value of the fusion control where the abscissa of the RET channel represents the fluorescence intensity, the ordinate represents the intensity of the forward scattered light, the abscissa of the Diff channel represents the intensity of the side scattered light, the ordinate represents the intensity of the fluorescence, and the abscissa of the Baso channel Indicates the intensity of the side scattered light, the ordinate represents the intensity of the forward scattered light, the abscissa of the NRBC channel represents the intensity of the fluorescence, and the ordinate represents the intensity of the forward scattered light;
  • Figure 16 is a simulation of reticulocyte preparation prepared by fluorescent dye G in the examples of the present application.
  • the RET channel abscissa indicates the fluorescence intensity.
  • the ordinate indicates the forward scattered light intensity
  • the Diff channel abscissa indicates the side scattered light intensity
  • the ordinate indicates the fluorescence intensity
  • the Baso channel abscissa indicates the side scattered light intensity
  • the ordinate indicates the forward scattered light intensity
  • the NRBC channel crosses The coordinates represent the fluorescence intensity and the ordinate represents the forward scattered light intensity;
  • Figure 17 is a scatter plot of reticulocyte simulated particles prepared by fluorescent dye H and platelet mimic particles containing reticulated platelets in the RET channel of Mindray BC-6 series blood cell analyzer, and the abscissa indicates fluorescence intensity. The ordinate indicates the forward scattered light intensity;
  • reticulocyte simulated particles prepared by the fluorescent dye H and platelet-simulated particles containing reticulated platelets in the examples of the present application, after adding leukocyte mimic particles, nucleated red blood cell mimic particles, red blood cell mimic particles, and preservation solution.
  • a scatter plot of the value of the fusion control where the abscissa of the RET channel represents the fluorescence intensity, the ordinate represents the intensity of the forward scattered light, the abscissa of the Diff channel represents the intensity of the side scattered light, the ordinate represents the intensity of the fluorescence, and the abscissa of the Baso channel Indicates the intensity of the side scattered light, the ordinate represents the intensity of the forward scattered light, the abscissa of the NRBC channel represents the intensity of the fluorescence, and the ordinate represents the intensity of the forward scattered light;
  • reticulocytes 1 is reticulocytes
  • 2 is platelets
  • 3 is reticulated platelets
  • 4 red blood cells
  • 5 lymphocytes
  • 6 monocytes
  • 7 is neutrophils
  • 8 is eosinophils.
  • the cells, 9 are basophils
  • 10 are nucleated red blood cells.
  • the protein fluorescent dye in the present application refers to a fluorescent dye that dyes proteins in the field of biotechnology.
  • the protein fluorescent dye suitable for use in the present application has the formula of N-hydroxysuccinimidation, as shown in Formula 1; preferably, the protein fluorescent dye is of Formula 2, Formula 3, Formula IV and At least one of the structures shown in Formula 5; more preferably in the fluorescent dye AH described in the present application At least one of them.
  • the present application uses non-nuclear red blood cells as raw materials, and the prepared simulated particles have membrane properties similar to those of reticulocyte simulated particles and reticulated platelets, which can satisfy Quality control requirements for hemolysis and non-hemolytic detection channels; the simulated particles prepared in this application have good stability and do not affect the counting and classification of other cellular particles.
  • the preparation method of the present application is as shown in FIG. 1 , and only the non-nucleated red blood cells need to be dyed, fixed, and adjusted and stored, and the process is relatively simple and convenient for processing.
  • the blood cell analyzer is a Mindray BC-6 series blood cell analyzer.
  • the fluorescent dye A is activated by N-hydroxysuccinimide and dissolved in an organic solvent to prepare a fluorescent dye A mother liquor.
  • the specific synthesis step of the activated dye in this example is: adding dye A, N-hydroxysuccinimide (NHS) and 1-(3-dimethylaminopropyl)-3-ethylcarbazone to dichloromethane.
  • the amine hydrochloride (EDC) can be obtained by stirring at room temperature for 1 hour, and the dye A after activation.
  • other organic solvents such as methanol, may also be used depending on the dye.
  • the reaction conditions can be adjusted according to conventional techniques in the art.
  • the preservation solution of this example is a commercially available preservation solution, and the following examples are the same as in the present example.
  • the preparation method of reticulocyte simulated particles is as follows:
  • RBC filtered red blood cells
  • washing liquid I centrifugal washing RBC twice; wherein, washing liquid I is a solution containing disodium hydrogen phosphate 2.0g / L, sodium dihydrogen phosphate 0.2g / L and sodium chloride 9.0g / L;
  • washing liquid I suspends cell pellet, add fluorescent dye A mother liquor, make the final concentration of fluorescent dye 100mg/L, add fluorescent dye to the surface layer of cell sediment for 3 minutes, make the fluorescent dye fully contact with the cells, then mix, the reaction ends. After that, the supernatant was removed by centrifugation, 4 volumes of washing solution II was added, and the supernatant was centrifuged; the washing solution II was a solution containing 35 g/L of sodium citrate and 0.2 g/L of citric acid;
  • washing liquid II suspension cell pellet adding 37-40% formaldehyde fixative to make it final concentration 0.1%, treated at room temperature for 2 hours; after the end of the fixation, the washing solution II adjusted the RBC to an appropriate concentration, centrifuged to remove the supernatant, and repeated washing twice;
  • the preparation method of platelet mimic particles is as follows:
  • RBC red blood cells
  • washing liquid I centrifugal washing sheep source RBC twice; wherein, washing liquid I is composed of disodium hydrogen phosphate 1.44g / L, potassium dihydrogen phosphate 0.27g / L, sodium chloride 8g / L and potassium chloride 0.2g /L solution;
  • washing liquid I suspends cell pellet, add fluorescent dye A mother liquor, make the final concentration of fluorescent dye 50mg/L, mix quickly after adding; mark at room temperature for 1 hour, mix 3-4 times during period, make fluorescent dye and cells full Contact, after the reaction is completed, add an equal volume of washing solution II to dilute, centrifuge to remove the supernatant, and wash the washing solution II repeatedly; the washing solution II is a solution containing sodium citrate 35g / L, citric acid 0.2g / L;
  • Washing liquid II suspends the cell pellet, adding 37-40% formaldehyde fixative to a final concentration of 0.5%, and treating at room temperature for 2 hours;
  • BSA bovine serum albumin
  • the preservation solution is suspended to the PLT count to an appropriate concentration, and chilled at 2 to 8 ° C, and the preparation of platelet mimic particles containing reticulated platelets is completed.
  • the leukocyte mimic particles, the red blood cell mimic particles, the nucleated red blood cell mimic particles are added to the reticulocyte simulated particles prepared in this example, and the platelet mimic particles containing the reticulated platelets are mixed in proportion to form a quality control substance, and the concentration of each component is as follows:
  • white blood cell simulation particle 2.8 ⁇ 10 9 /L red blood cell simulation particle 2.8 ⁇ 10 12 /L
  • platelet simulation particle 75 ⁇ 10 9 /L platelet simulation particle 75 ⁇ 10 9 /L
  • reticulocyte simulated particle 0.02 ⁇ 10 12 /L nucleated red blood cell simulation particle 0.11 ⁇ 10 9 /L.
  • white blood cell simulation particle 20 ⁇ 10 9 /L red blood cell simulation particle 5.2 ⁇ 10 12 /L, platelet simulation particle 490 ⁇ 10 9 /L, reticulocyte simulated particle 0.26 ⁇ 10 12 /L, nucleated red blood cell simulation particle 0.8 ⁇ 10 9 /L.
  • the blood cell analyzer for fluorescence staining is used to detect the reticulocyte simulated particles, platelet mimic particles and quality control materials prepared in this example.
  • the scatter plot of the reticulocyte simulated particles and platelet mimic particles is shown in Figure 2, where the left image is the scatter plot of the reticulocyte simulated particles, and the right panel is the scatter plot of the platelet mimetic particles.
  • 1 is the net.
  • Weaving red blood cells 2 is platelets
  • 3 is reticulated platelets; the scatter plots of low, medium and high values of fusion control are shown in Figure 3.
  • the first behavior is a low-value scatter plot of the quality control.
  • the second behavioral scatter plot, the third behavioral high value scatter plot 1 is reticulocyte, 2 is platelet, 3 is reticulated platelet, 4 is red blood cell, 5 is lymphocyte, 6 is monocyte, 7 is Neutrophils, 8 are eosinophils, 9 are basophils, and 10 are nucleated red blood cells.
  • the results in Fig. 2 show that the reticulocyte simulated particles and platelet mimic particles prepared in this example have a scatter plot distribution of fresh reticulocytes and platelets, and in the scatter plot of platelet mimic particles, the upper right portion of platelet 2 That is, reticulated platelets 3; the results of Fig. 3 show that the reticulocyte simulated particles and platelet mimic particles prepared in this example do not interfere with the counting and classification of other particle channels such as white blood cells and nucleated red blood cells, and can be used for preparing blood quality control substances. Or calibrator.
  • the fluorescent dye B is activated by N-hydroxysuccinimide and dissolved in an organic solvent to prepare a fluorescent dye B mother liquor.
  • washing liquid I centrifugal washing RBC twice, washing liquid I is a solution containing potassium dihydrogen phosphate 1.41g / L, potassium dihydrogen phosphate 0.27g / L and potassium chloride 11.8g / L;
  • washing liquid II suspends cell pellet, add fluorescent dye B mother liquor, make the final concentration of fluorescent dye 50mg/L, mix quickly after adding; mark at room temperature for 2 hours, mix 3-4 times during period, make fluorescent dye and cells full Contact, after the reaction is completed, add 4 volumes of washing solution II, centrifuge to remove the supernatant, and wash the washing solution II repeatedly;
  • the washing solution II is sodium citrate 17g / L, citric acid 0.1g / L and sodium chloride 5g /L solution;
  • washing solution I is washed twice by centrifugation; washing solution I is a solution containing disodium hydrogen phosphate 2.0 g/L, sodium dihydrogen phosphate 0.2 g/L and sodium chloride 9.0 g/L;
  • washing liquid I suspends cell pellet, add fluorescent dye B mother liquor, make the final concentration of fluorescent dye 5mg/L, mix quickly after adding; mark at room temperature for 15 minutes, mix 3-4 times during period, make fluorescent dye and cells full Contact, after the reaction is completed, add an equal volume of washing solution II to dilute, centrifuge to remove the supernatant, and repeat the washing twice; washing solution II is a solution containing sodium citrate 17g / L, citric acid 0.1g / L and sodium chloride 5g / L ;
  • the preservation solution is suspended to the PLT count to an appropriate concentration, and chilled at 2 to 8 ° C, and the preparation of platelet mimic particles containing reticulated platelets is completed.
  • the leukocyte mimic particles, the red blood cell mimic particles, the nucleated red blood cell mimic particles are added to the reticulocyte simulated particles prepared in this example, and the platelet mimic particles are mixed in proportion to form a fusion quality control, such that:
  • the blood cell analyzer for fluorescence staining is used to detect the reticulocyte simulated particles, platelet mimic particles and quality control materials prepared in this example.
  • the scatter plot of the reticulocyte-simulating particles and platelet-simulated particles is shown in Figure 5.
  • the left image is the scatter plot of the reticulocyte simulated particles, and the right is the scatter plot of the platelet-simulated particles.
  • 1 is the net.
  • the erythrocytes, 2 are platelets, and 3 are reticulated platelets; the scatter plot of the fusion control is shown in Figure 6.
  • 1 is reticulocytes
  • 2 is platelets
  • 3 is reticulated platelets
  • 4 red blood cells.
  • Fig. 5 is lymphocytes, 6 is monocytes, 7 is neutrophils, 8 is eosinophils, 9 is Basophils, 10 are nucleated red blood cells.
  • the results in Fig. 5 show that the reticulocyte simulated particles and platelet mimic particles prepared in this example have a scatter plot distribution of fresh reticulocytes and platelets, and in the scatter plot of platelet mimic particles, the upper right portion of platelet 2 That is, reticulated platelets 3; the results of Fig. 6 show that the reticulocyte simulated particles and platelet mimic particles prepared in this example do not interfere with the counting and classification of other particle channels such as leukocytes and nucleated red blood cells, and can be used for preparing blood quality control substances. Or calibrator.
  • the fluorescent dye C is activated by N-hydroxysuccinimide and dissolved in an organic solvent to prepare a fluorescent dye C mother liquor.
  • washing liquid I was washed twice by RBC; washing liquid I was a solution containing 1.44 g/L of disodium hydrogen phosphate, 0.27 g/L of potassium dihydrogen phosphate, 8 g/L of sodium chloride and 0.2 g/L of potassium chloride. ;
  • Washing liquid I suspends cell pellet, add fluorescent dye C mother liquor, make the final concentration of fluorescent dye 10mg/L, mix quickly after adding; mark at room temperature for 20 minutes, mix 3-4 times during period, make fluorescent dye and cells full Contact, after the reaction is completed, add 4 times the volume of the washing liquid II, centrifuge to remove the supernatant, and repeat the washing once; the washing liquid II is 17 g/L containing sodium citrate, 0.1 g/L of citric acid and 5 g/L of sodium chloride. Solution
  • Washing liquid II suspends cell pellet, adding 50% glutaraldehyde to a final concentration of 0.05%, and treating at room temperature for 2 hours; after the end of fixation, using RBA with a final concentration of BSA of 1% to adjust RBC count to appropriate concentration , centrifuge to remove the supernatant, repeat the washing 2 times;
  • the preservation solution is suspended to the RBC count to an appropriate concentration to obtain the reticulocyte simulated particles of this example.
  • washing solution I is washed twice by centrifugation; washing solution I is a solution containing disodium hydrogen phosphate 2.0 g/L, sodium dihydrogen phosphate 0.2 g/L and sodium chloride 9.0 g/L;
  • Washing liquid I suspends cell pellet, add a certain amount of fluorescent dye C mother liquor, and make the final concentration of fluorescent dye 5mg/L, and mix quickly after adding. Mark at room temperature for 15 minutes, mix for 3-4 times, so that the fluorescent dye is in full contact with the cells. After the reaction is completed, add an equal volume of washing solution II to dilute, centrifuge to remove the supernatant, and repeat the washing once; Washing solution II is sodium citrate. 17g/L, lemon a solution of citric acid 0.1 g/L and sodium chloride 5 g/L;
  • the preservation solution is suspended to the PLT count to an appropriate concentration, and chilled at 2 to 8 ° C, and the preparation of platelet mimic particles containing reticulated platelets is completed.
  • the leukocyte mimic particles, the red blood cell mimic particles, the nucleated red blood cell mimic particles are added to the reticulocyte simulated particles prepared in this example, and the platelet mimic particles are mixed in proportion to form a fusion quality control, such that:
  • the blood cell analyzer for fluorescence staining is used to detect the reticulocyte simulated particles, platelet mimic particles and quality control materials prepared in this example.
  • the scatter plot of the reticulocyte simulated particles and platelet-simulated particles is shown in Figure 7, where the left image is the scatter plot of the reticulocyte simulated particles, and the right panel is the scatter plot of the platelet-simulated particles.
  • 1 is the net.
  • the erythrocytes, 2 are platelets, and 3 are reticulated platelets; the scatter plot of the fusion control is shown in Figure 8.
  • 1 is reticulocytes
  • 2 is platelets
  • 3 is reticulated platelets
  • 4 red blood cells.
  • Fig. 7 show that the reticulocyte simulated particles and platelet mimic particles prepared in this example have a scattergram distribution of fresh reticulocytes and platelets, and in the scattergram of platelet mimic particles, the right part of platelet 2 is Reticulated platelets 3; the results of Figure 8 show that the reticulocyte simulated particles and platelet mimic particles prepared in this example do not interfere with the counting and classification of other particle channels such as white blood cells and nucleated red blood cells, and can be used to prepare blood quality control or Calibrator.
  • the fluorescent dye D is activated by N-hydroxysuccinimide and dissolved in an organic solvent to prepare a fluorescent dye D mother liquor.
  • washing solution I was washed twice by RBC; washing solution I was a solution containing 1.44 g/L of disodium hydrogen phosphate, 0.27 g/L of potassium dihydrogen phosphate, 8 g/L of sodium chloride and 0.2 g/L of potassium chloride. ;
  • washing liquid I suspends cell pellet, add fluorescent dye D mother liquor, make the final concentration of fluorescent dye 40mg/L, mix quickly after adding; mark at 2 ⁇ 8°C for 30 minutes, mix 1-2 times to make fluorescent dye Intimate contact with the cells, after the reaction is completed, add 4 times the volume of the washing solution II, centrifuge to remove the supernatant, and repeat the washing once;
  • the washing solution II is sodium citrate 17g / L, citric acid 0.1g / L and sodium chloride 5g /L solution;
  • washing liquid II suspension cell pellet add 50% glutaraldehyde to a final concentration of 0.05%, overnight at room temperature; after the end of the fixation, use BSA final concentration of 1% of the washing solution II to adjust the RBC count to the appropriate concentration, centrifugation Remove the supernatant and repeat the washing twice;
  • the preservation solution is suspended to the RBC count to an appropriate concentration to obtain reticulocyte simulated particles.
  • washing liquid I centrifugal washing sheep source RBC twice; washing liquid I is containing disodium hydrogen phosphate 1.44g / L, potassium dihydrogen phosphate 0.27g / L, sodium chloride 8g / L and potassium chloride 0.2g / L The solution;
  • washing liquid I suspends cell pellet, add a certain amount of fluorescent dye D mother liquor, make the final concentration of fluorescent dye 20mg/L, mix quickly after adding; mark at room temperature for 1 hour, mix 3-4 times during period, make fluorescent dye and The cells are fully contacted, and after the reaction is completed, an equal volume of washing solution II is added to be diluted, and the supernatant is centrifuged, and the washing is repeated twice; the washing liquid II is a solution containing 35 g/L of sodium citrate and 0.2 g/L of citric acid;
  • the preservation solution is suspended to the PLT count to an appropriate concentration, and chilled at 2 to 8 ° C, and the preparation of platelet mimic particles containing reticulated platelets is completed.
  • the blood cell analyzer for fluorescence staining is used to detect the reticulocyte simulated particles, platelet mimic particles and quality control materials prepared in this example.
  • the scatter plot of the reticulocyte simulated particles and platelet mimic particles is shown in Fig. 9.
  • the left graph is the scatter plot of the reticulocyte simulated particles, and the right graph is the scatter plot of the platelet mimic particles.
  • 1 is the net.
  • the erythrocytes, 2 are platelets, and 3 are reticulated platelets; the scatter plot of the fusion control is shown in Figure 10.
  • 1 is reticulocytes
  • 2 is platelets
  • 3 is reticulated platelets
  • 4 red blood cells.
  • Fig. 9 show that the reticulocyte simulated particles and platelet mimic particles prepared in this example have a scattergram distribution of fresh reticulocytes and platelets, and in the scattergram of platelet mimic particles, the right part of platelet 2 is Reticulated platelets 3;
  • Figure 10 shows that the reticulocyte simulated particles and platelet mimic particles prepared in this example do not interfere with the counting and classification of other particle channels such as white blood cells and nucleated red blood cells, and can be used to prepare blood quality control or Calibrator.
  • the fluorescent dye E is activated by N-hydroxysuccinimide and dissolved in an organic solvent to prepare a fluorescent dye E mother liquor.
  • washing liquid I was washed twice by RBC; washing liquid I was a solution containing 1.44 g/L of disodium hydrogen phosphate, 0.27 g/L of potassium dihydrogen phosphate, 8 g/L of sodium chloride and 0.2 g/L of potassium chloride. ;
  • Washing liquid I suspends cell pellet, add fluorescent dye E mother liquor, make the final concentration of fluorescent dye 15mg/L, mix quickly after adding; mark at room temperature for 30 minutes, mix 3-4 times during period, make fluorescent dye and cells full Contact, after the reaction is completed, add 4 volumes of washing solution I, centrifuge to remove the supernatant, and repeat the washing once;
  • Washing liquid II suspends the cell pellet, adding 37-40% formaldehyde fixative to a final concentration of 0.1%, and treating at room temperature for 1 hour; after the end of fixation, the RBC count is adjusted to the final concentration of BSA 0.5% of washing solution II to At appropriate concentration, the supernatant was centrifuged and washed twice; the washing solution II was a solution containing 17 g/L of sodium citrate, 0.1 g/L of citric acid and 5 g/L of sodium chloride;
  • the preservation solution is suspended to the RBC count to an appropriate concentration to obtain reticulocyte simulated particles.
  • washing solution I is washed twice by centrifugation; washing solution I is a solution containing disodium hydrogen phosphate 2.0 g/L, sodium dihydrogen phosphate 0.2 g/L and sodium chloride 9.0 g/L;
  • washing liquid I suspends cell pellet, add fluorescent dye E mother liquor, make the final concentration of fluorescent dye 10mg/L, mix quickly after adding; mark at room temperature for 1 hour, mix 3-4 times during period, make fluorescent dye and cells full Contact, after the reaction is completed, add 4 times volume of washing solution II to dilute, centrifuge to remove the supernatant, repeat washing 1 time; washing liquid II is sodium citrate 17g / L, citric acid 0.1g / L and sodium chloride 5g / L Solution
  • Washing liquid II suspends the cell pellet, adding 37-40% formaldehyde fixative to a final concentration of 0.8%, and treating at room temperature overnight;
  • the preservation solution is suspended to the PLT count to an appropriate concentration, and chilled at 2 to 8 ° C, and the preparation of platelet mimic particles containing reticulated platelets is completed.
  • the blood cell analyzer for fluorescence staining is used to detect the reticulocyte simulated particles, platelet mimic particles and quality control materials prepared in this example.
  • the scatter plot of the reticulocyte simulated particles and platelet mimic particles is shown in Figure 11, where the left image is the scatter plot of the reticulocyte simulated particles, and the right panel is the scatter plot of the platelet mimetic particles.
  • 1 is the net.
  • the erythrocytes, 2 are platelets, and 3 are reticulated platelets; the scatter plot of the fusion control is shown in Figure 12.
  • 1 is reticulocytes
  • 2 is platelets
  • 3 is reticulated platelets
  • 4 red blood cells.
  • the results in Figure 11 show that the reticulocyte simulated particles and platelet mimic particles prepared in this example have fresh blood reticulocytes and platelets.
  • the counting and classification of other particle channels, such as nucleated red blood cells, can be used to prepare blood controls or calibrators.
  • the fluorescent dye F is activated by N-hydroxysuccinimide and dissolved in an organic solvent to prepare a fluorescent dye F mother liquor.
  • washing liquid I was washed twice by RBC; washing liquid I was a solution containing 1.44 g/L of disodium hydrogen phosphate, 0.27 g/L of potassium dihydrogen phosphate, 8 g/L of sodium chloride and 0.2 g/L of potassium chloride. ;
  • washing solution II was sodium citrate 17 g/L, citric acid 0.1 g/L and sodium chloride 5 g/ a solution of L;
  • Washing liquid II suspends the cell pellet, and adds 50% glutaraldehyde to a final concentration of 0.05%, and treats at room temperature for 3 hours. After the end of the fixation, the RBC count was adjusted to an appropriate concentration using the washing solution II with a final concentration of BSA of 0.6%, and the supernatant was centrifuged, and the washing was repeated twice;
  • the preservation solution is suspended to the RBC count to an appropriate concentration to obtain reticulocyte simulated particles.
  • washing solution I is washed twice by centrifugation; washing solution I is a solution containing disodium hydrogen phosphate 2.0 g/L, sodium dihydrogen phosphate 0.2 g/L and sodium chloride 9.0 g/L;
  • washing liquid II is sodium citrate 17 g/L, citric acid 0.1 g/L and a solution of sodium chloride 5g / L;
  • Washing liquid II suspends the cell pellet, adding glutaraldehyde fixative to a final concentration of 0.015%, and treating at room temperature overnight.
  • the preservation solution is suspended to the PLT count to an appropriate concentration, and chilled at 2 to 8 ° C, and the preparation of platelet mimic particles containing reticulated platelets is completed.
  • the blood cell analyzer for fluorescence staining is used to detect the reticulocyte simulated particles, platelet mimic particles and quality control materials prepared in this example.
  • the scatter plot of the reticulocyte simulated particles and platelet mimic particles is shown in Figure 13, where the left image is the scatter plot of the reticulocyte simulated particles, and the right panel is the scatter plot of the platelet mimetic particles.
  • 1 is the net.
  • the erythrocytes, 2 are platelets, and 3 are reticulated platelets; the scatter plot of the fusion control is shown in Figure 14.
  • 1 is reticulocytes
  • 2 is platelets
  • 3 is reticulated platelets
  • 4 red blood cells.
  • Fig. 13 show that the reticulocyte simulated particles and platelet mimic particles prepared in this example have a scattergram distribution of fresh reticulocytes and platelets, and in the scattergram of platelet mimic particles, the right part of platelet 2 is Reticulated platelets 3;
  • Figure 14 shows that the reticulocyte simulated particles and platelet mimic particles prepared in this example do not interfere with the counting and classification of other particle channels such as white blood cells and nucleated red blood cells, and can be used to prepare blood quality control or Calibrator.
  • the fluorescent dye G is activated by N-hydroxysuccinimide and dissolved in an organic solvent to prepare a fluorescent dye G mother liquor.
  • washing liquid I was washed twice by RBC; washing liquid I was a solution containing 1.44 g/L of disodium hydrogen phosphate, 0.27 g/L of potassium dihydrogen phosphate, 8 g/L of sodium chloride and 0.2 g/L of potassium chloride. ;
  • washing liquid I suspends cell pellet, add fluorescent dye G mother liquor, make the final concentration of fluorescent dye 85mg/L, mix quickly after adding; mark at 2 ⁇ 8°C for 45 minutes, mix 1-2 times, make fluorescent dye Intimate contact with the cells, after the reaction is completed, add 4 times the volume of the washing solution II, centrifuge to remove the supernatant, and repeat the washing once;
  • the washing solution II is sodium citrate 17g / L, citric acid 0.1g / L and sodium chloride 5g /L solution;
  • the preservation solution is suspended to the RBC count to an appropriate concentration to obtain reticulocyte simulated particles.
  • washing liquid I centrifugal washing sheep source RBC twice; washing liquid I is containing disodium hydrogen phosphate 1.44g / L, potassium dihydrogen phosphate 0.27g / L, sodium chloride 8g / L and potassium chloride 0.2g / L The solution;
  • washing solution II was sodium citrate 17 g/L, citric acid 0.1 g/L and sodium chloride 5 g/ a solution of L;
  • Washing liquid II suspends cell pellet, adding 37-40% formaldehyde fixative to a final concentration of 0.3%, and treating at room temperature for 4 hours;
  • the preservation solution is suspended to the PLT count to an appropriate concentration, and chilled at 2 to 8 ° C, and the preparation of platelet mimic particles containing reticulated platelets is completed.
  • the blood cell analyzer used for the fluorescence detection method is the reticulation prepared in this example. Red blood cell mimics particles, platelet mimic particles, and controls were tested.
  • the scatter plot of the reticulocyte simulated particles and platelet mimic particles is shown in Figure 15, where the left image is the scatter plot of the reticulocyte simulated particles, and the right panel is the scatter plot of the platelet mimetic particles.
  • 1 is the net.
  • the erythrocytes, 2 are platelets, and 3 are reticulated platelets; the scatter plot of the fusion control is shown in Figure 16.
  • 1 is reticulocytes
  • 2 is platelets
  • 3 is reticulated platelets
  • 4 red blood cells.
  • Fig. 15 show that the reticulocyte simulated particles and platelet mimic particles prepared in this example have a scattergram distribution of fresh reticulocytes and platelets, and in the scattergram of platelet mimic particles, the right part of platelet 2 is Reticulated platelets 3;
  • Figure 16 shows that the reticulocyte simulated particles and platelet mimic particles prepared in this example do not interfere with the counting and classification of other particle channels such as leukocytes and nucleated red blood cells, and can be used to prepare blood quality control or Calibrator.
  • the fluorescent dye H is activated by N-hydroxysuccinimide and dissolved in an organic solvent to prepare a fluorescent dye H mother liquor.
  • washing liquid I was washed twice by RBC; washing liquid I was a solution containing 1.44 g/L of disodium hydrogen phosphate, 0.27 g/L of potassium dihydrogen phosphate, 8 g/L of sodium chloride and 0.2 g/L of potassium chloride. ;
  • Washing liquid II suspends the cell pellet, adding 37-40% formaldehyde fixative to a final concentration of 0.5%, and treating at room temperature for 2 hours; after the end of the fixation, the RBC count is adjusted to the final concentration of BSA with a BSA of 1% to At appropriate concentration, the supernatant is centrifuged and washed twice; the washing solution II is a solution containing 35 g/L of sodium citrate and 0.2 g/L of citric acid;
  • the preservation solution is suspended to the RBC count to an appropriate concentration to obtain reticulocyte simulated particles.
  • washing solution I is washed twice by centrifugation; washing solution I is disodium hydrogen phosphate containing 2.0 g/L, phosphoric acid a solution of sodium dihydrogen 0.2 g/L and sodium chloride 9.0 g/L;
  • washing solution II is sodium citrate 35 g/L and citric acid 0.2 g/ a solution of L;
  • the preservation solution is suspended to the PLT count to an appropriate concentration, and chilled at 2 to 8 ° C, and the preparation of platelet mimic particles containing reticulated platelets is completed.
  • the blood cell analyzer for fluorescence staining is used to detect the reticulocyte simulated particles, platelet mimic particles and quality control materials prepared in this example.
  • the scatter plot of the reticulocyte simulated particles and platelet mimic particles is shown in Figure 17, where the left image is the scatter plot of the reticulocyte simulated particles, and the right panel is the scatter plot of the platelet mimetic particles.
  • 1 is the net.
  • the erythrocytes, 2 are platelets, and 3 are reticulated platelets; the scatter plot of the fusion control is shown in Figure 18.
  • 1 is reticulocytes
  • 2 is platelets
  • 3 is reticulated platelets
  • 4 red blood cells.
  • Fig. 17 show that the reticulocyte simulated particles and platelet mimic particles prepared in this example have a scattergram distribution of fresh reticulocytes and platelets, and in the scattergram of platelet mimic particles, the right part of platelet 2 is Reticulated platelets 3;
  • Figure 18 shows that the reticulocyte simulated particles and platelet mimic particles prepared in this example do not interfere with the counting and classification of other particle channels such as leukocytes and nucleated red blood cells, and can be used to prepare blood quality control or Calibrator.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Quality & Reliability (AREA)
  • Dispersion Chemistry (AREA)
  • Ecology (AREA)
  • Biophysics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

一种网织红细胞模拟粒子、血小板模拟粒子制备方法及质控物。网织红细胞模拟粒子制备方法，采用N-羟基琥珀酰亚胺活化的蛋白荧光染料，对体积60-120fL的哺乳动物无核红细胞染色，并对无核红细胞固定处理，制成网织红细胞模拟粒子。血小板模拟粒子制备采用体积2-25fL的哺乳动物无核红细胞，其余与网织红细胞模拟粒子相同。制备方法包括：采用N-羟基琥珀酰亚胺活化的蛋白荧光染料对不同体积的哺乳动物无核红细胞染色，分别获得网织红细胞模拟粒子和血小板模拟粒子，其散点图荧光与体积方向接近新鲜血网织红细胞、网织血小板和血小板散点图分布；制备的模拟粒子稳定性好，不干扰其它细胞粒子的计数分类。

Description

网织红细胞模拟粒子、血小板模拟粒子制备方法及质控物 技术领域
本申请涉及血液质控物领域，特别是涉及一种网织红细胞模拟粒子制备方法、血小板模拟粒子制备方法，以及包含所制备的网织红细胞模拟粒子和血小板模拟粒子的质控物。
背景技术
网织红细胞是尚未完全成熟的红细胞，是反映骨髓红系造血功能以及判断贫血和相关疾病疗效的重要指标，对血液病的诊断和治疗反应观察均有重要意义。网织红细胞相关参数是中、高端血细胞分析仪提供的一项重要信息。血液质控物是一种含有单一或多组分血细胞或血细胞模拟物的液体，具备如同血液一样的可检测特性，用于日常监控血液分析仪的准确性和精确性。网织红细胞模拟粒子和血小板模拟粒子就是血液质控物中分别模拟网织红细胞和血小板的血细胞模拟物。
网织红细胞模拟粒子存在多种制备方法，方法一：通过渗透压的变化使红细胞的胞膜膨胀，产生小孔，然后将核酸注入胞内，模拟网织红细胞的形态；该制备方法对工艺要求高，工艺操作难度大，量产效率较低，并且，细胞经过了涨缩，其膜强度降低。方法二：通过富集提纯贫血动物，如：猪，的血液中网织红细胞，固定剂处理实现粒子稳定性，该制备方法网织红细胞提纯难度大，动物血原材料成本较高，且粒子体积参数无法有效模拟人网织红细胞分布。方法三：通过氧化外源核酸，形成醛基与人红细胞膜表面交联，实现粒子荧光信号模拟，该方法的工艺步骤过多，反应条件复杂不可控，降低了工艺实用性及可控性。
血小板模拟粒子也存在多种制备方法。方法一：以人源血小板为原材料，通过使用聚乙二醇(缩写PEG)增强血小板稳定性，该制备方法血小板易活化进而引发聚集效应，导致质控品失效，同时人源血小板商业来源价格昂贵。方法二：采用低成本的山羊红细胞为原材料制备血小板模拟粒子，该方法可以减少人源血小板的聚集效应，但是，该方法需要对山羊红细胞进行皱缩处理，以调整其体积大小来制备血小板模拟粒子，无法有效模拟人血小板体积分布，并且，皱缩的羊红细胞在等渗的保存液中存在形变恢复的趋势。方法三：采用不同红细胞体积特征的山 羊血混合，模拟人血小板体积分布，但其加工工艺过于复杂，同时因固定后的血小板粒子会对溶血剂有抗溶作用，当含有血小板和白细胞的质控物用于检测时，该方法制备的血小板模拟粒子，会导致白细胞计数假性升高，影响质控的准确性。方法四：通过弱固定动物血红细胞，满足溶血剂作用下可溶解需求，然后通过不同渗透压环境下调至体积大小，混合不同体积大小的红细胞，实现近似人血小板体积分布，但工艺实用性及可控性仍然是较大挑战。
因此，亟需一种简单、经济，而又适用于工业化生产的网织红细胞模拟粒子和血小板模拟粒子的制备方法，以满足血液质控物的生产和使用需求。
发明内容
本申请的目的是提供一种新的网织红细胞模拟粒子、血小板模拟粒子的制备方法，以及含有所制备的网织红细胞模拟粒子和血小板模拟粒子的质控物。
为了实现上述目的，本申请采用了以下技术方案：
本申请的一方面公开了一种网织红细胞模拟粒子的制备方法，包括采用N-羟基琥珀酰亚胺活化的具有羧基的蛋白荧光染料，对哺乳动物无核红细胞进行染色，并对哺乳动物无核红细胞进行固定处理，制成网织红细胞模拟粒子；其中，固定处理可以在染色前或染色后进行，哺乳动物无核红细胞的体积大小为60-120fL，哺乳动物无核红细胞优选为人源红细胞、兔红细胞、牛红细胞、猪红细胞、马红细胞或豚鼠红细胞。
需要说明的是，本申请的关键在于采用N-羟基琥珀酰亚胺活化的蛋白荧光染料对体积大小为60-120fL的哺乳动物无核红细胞进行染色；其中，限定哺乳动物无核红细胞的体积大小为60-120fL，使得制备出的模拟粒子能够有效的模拟网织红细胞的荧光和体积性质。并且，本申请采用N-羟基琥珀酰亚胺活化的蛋白荧光染料染色获得的模拟粒子，具有和网织红细胞类似的膜性质，能够满足溶血和非溶血的检测通道的质控需求。N-羟基琥珀酰亚胺活化的蛋白荧光染料是指对蛋白荧光染料的羧基进行N-羟基琥珀酰亚胺化，这样可以使蛋白荧光染料稳定的结合在哺乳动物无核红细胞膜表面，保障了模拟粒子中蛋白荧光染料连接的稳定性。还需要说明的是，一般而言，体积大小为60-120fL的哺乳动物无核红细 胞主要包括人源红细胞、兔红细胞、牛红细胞、猪红细胞、马红细胞和豚鼠红细胞等，这些都可以用于制备本申请的网织红细胞模拟粒子；可以理解，本申请的网织红细胞模拟粒子，只要其原材料无核红细胞的体积大小满足60-120fL都可以用于本申请，不只限于人源红细胞、兔红细胞、牛红细胞、猪红细胞、马红细胞和豚鼠红细胞。还需要说明的是，本申请中，固定处理为弱固定处理，即在固定细胞的同时又能保持一定的细胞活性，使之能够长期稳定，同时能够在溶血剂的作用下溶解。
可以理解，本申请的制备方法可以简单而有效的获得网织红细胞模拟粒子，在本申请制备的网织红细胞模拟粒子基础上，还可以进一步的对其进行球形化处理，以满足不同的使用需求。当然，球形化处理的具体步骤可以整合到本申请的制备方法中，在此不做具体限定。
优选的，本申请的制备方法中，采用N-羟基琥珀酰亚胺活化的具有羧基的蛋白荧光染料，对哺乳动物无核红细胞进行染色，包括以下步骤，
提取哺乳动物无核红细胞；
提供经N-羟基琥珀酰亚胺活化的蛋白荧光染料，蛋白荧光染料中具有可供活化的羧基，羧基被N-羟基琥珀酰亚胺活化；
将N-羟基琥珀酰亚胺活化的蛋白荧光染料与哺乳动物无核红细胞孵育，对哺乳动物无核红细胞进行染色，获得染色的红细胞。
优选的，本申请的制备方法还包括对经过染色和固定的细胞进行洗涤。
可以理解，洗涤的目的是去除多余或者结合不稳定的蛋白荧光染料和固定剂，以免对后续步骤或者对融合质控物的其它组分造成影响，洗涤采用常规的缓冲液，如含柠檬酸和柠檬酸钠的混合溶液，或者柠檬酸、柠檬酸钠和氯化钠的混合溶液，在此不做具体限定。
优选的，N-羟基琥珀酰亚胺活化的具有羧基的蛋白荧光染料为通式一所示结构，
通式一
Figure PCTCN2017071755-appb-000001
通式一中，R为蛋白荧光染料，n为1-4的整数，n值取决于蛋白荧光染料的羧基个数。
优选的，蛋白荧光染料为通式二、通式三、通式四和通式五所示结构的至少一种，
通式二
Figure PCTCN2017071755-appb-000002
通式三
Figure PCTCN2017071755-appb-000003
通式四
Figure PCTCN2017071755-appb-000004
通式五
Figure PCTCN2017071755-appb-000005
通式二至通式五中，m为0、1、2或3，R1、R2各自独立地选自磺酸基、卤素原子或者氢原子；
R3和R4各自独立地选自烷基或含羧基的烷基，并且，R3和R4中至少有一个为含羧基的烷基；
R5、R6各自独立地选自磺酸基、卤素原子、烷基或者氢原子。
需要说明的是，通式二至通式五中，各自的R1、R2、R3、R4、R5或R6的基团选择互不影响。
优选的，蛋白荧光染料为荧光染料A-H中的至少一种，
荧光染料A的结构式为
Figure PCTCN2017071755-appb-000006
荧光染料B的结构式为
Figure PCTCN2017071755-appb-000007
荧光染料C的结构式为
Figure PCTCN2017071755-appb-000008
荧光染料D的结构式为
Figure PCTCN2017071755-appb-000009
荧光染料E的结构式为
Figure PCTCN2017071755-appb-000010
荧光染料F的结构式为
Figure PCTCN2017071755-appb-000011
荧光染料G的结构式为
Figure PCTCN2017071755-appb-000012
荧光染料H的结构式为
Figure PCTCN2017071755-appb-000013
优选的，固定处理采用的固定剂为重金属盐、甲醛、丙酮醛、戊二醛和多聚甲醛中的至少一种；
优选的，甲醛、丙酮醛、戊二醛或多聚甲醛的反应浓度为体积比0.005％-1％。
优选的，重金属盐为重铬酸盐，更优选为重铬酸钾或重铬酸。
优选的，本申请的制备方法，还包括对哺乳动物无核红细胞进行球形化处理。
本申请的另一面公开了一种本申请的制备方法制备的网织红细胞模拟粒子。
本申请的另一面公开了一种血小板模拟粒子的制备方法，包括采用N-羟基琥珀酰亚胺活化的具有羧基的蛋白荧光染料，对哺乳动物无核红细胞进行染色，并对哺乳动物无核红细胞进行固定处理，制成血小板模拟粒子；固定处理可以在染色前或染色后进行，哺乳动物无核红细胞的体积大小为2-25fL，哺乳动物无核红细胞优选为山羊源红细胞或绵羊红细胞。
需要说明的是，本申请的关键在于采用N-羟基琥珀酰亚胺活化的蛋白荧光染料对体积大小为2-25fL的哺乳动物无核红细胞进行染色；其中，限定哺乳动物无核红细胞的体积大小为2-25fL，使得制备出的模拟粒子能够有效的模拟血小板的荧光和体积性质。并且，本申请采用N-羟基琥珀酰亚胺活化的蛋白荧光染料染色获得的模拟粒子，具有和血小板类似的膜性质，能够满足溶血和非溶血的检测通道的质控需求。本申请的血小板模拟粒子制备方法和网织红细胞模拟粒子制备方法，两者的相同点在于，采用相同的N-羟基琥珀酰亚胺活化的蛋白荧光染料进行染色，而两者的关键区别在于，采用不同体积大小的哺乳动物无核红细胞原材料。经本申请的研究证实，采用本申请的制备方法，体积大小为60-120fL的哺乳动物无核红细胞能够模拟出网织红细胞，体积大小为2-25fL的哺乳动物无核红细胞能够模拟出血小板。还需要说明的是，一般来说，体积大小为2-25fL的哺乳动物无核红细胞主要包括山羊源红细胞或绵羊红细胞，两者都可以用于制备本申请的血小板模拟粒子；可以理解，本申请的血小板模拟粒子，只要其原材料红细胞的体积大小满足2-25fL都可以用于本申请，不只限于山羊源红细胞或绵羊红细胞。
可以理解，本申请的制备方法可以简单而有效的获得血小板模拟粒 子，在本申请制备的血小板模拟粒子基础上，还可以进一步的对其进行球形化处理，以满足不同的使用需求。当然，球形化处理的具体步骤可以整合到本申请的制备方法中，在此不做具体限定。
本申请的再一面公开了本申请的制备方法制备的血小板模拟粒子，并且，血小板模拟粒子中含有网织血小板模拟粒子。
本申请的再一面公开了一种血液分析仪用的质控物或校准物，其中含有本申请的网织红细胞模拟粒子和/或本申请的血小板模拟粒子。
优选的，质控物或校准物中还含有白细胞模拟粒子、红细胞模拟粒子和有核红细胞模拟粒子中的至少一种。
需要说明的是，本申请的质控物或校准物中，可以根据不同的使用需求调整织红细胞模拟粒子、血小板模拟粒子、白细胞或白细胞模拟粒子、红细胞或红细胞模拟粒子等组份的浓度，以配制出低值、中值、高值质控物或校准物，在此不做具体限定。
本申请的再一面公开了一种血液分析仪用的细胞模拟粒子，该细胞模拟粒子为表面交联有至少一个蛋白荧光染料分子的哺乳动物无核红细胞。
需要说明的是，本申请的关键在于，利用哺乳动物无核红细胞表面交联染料来模拟其它血细胞的荧光和体积性质，制备血细胞模拟粒子，用于血液分析仪的质控。
在本申请的优选方案中，特别指出体积大小为60-120fL的哺乳动物无核红细胞交联蛋白荧光染料分子，得到的细胞模拟粒子，其散点图荧光与体积方向，正好符合网织红细胞的分布，可以模拟网织红细胞。基于此，本申请提出了网织红细胞模拟粒子的制备方法。
更优选的，体积大小为60-120fL的哺乳动物无核红细胞为人源红细胞、兔红细胞、牛红细胞、猪红细胞、马红细胞或豚鼠红细胞。
本申请的另一优选方案中，指出体积大小为2-25fL的哺乳动物无核红细胞交联蛋白荧光染料分子，得到的细胞模拟粒子，其散点图荧光与体积方向，正好符合网织血小板和血小板的分布，可以模拟带网织血小板的血小板。因此，本申请提出了血小板模拟粒子的制备方法。
更优选的，体积大小为2-25fL的哺乳动物无核红细胞为山羊源红细胞或绵羊红细胞。
需要说明的是，以上两个优选方案是利用了交联反应的差别，形成 具有差别的粒子荧光强度，从而分别得到网织红细胞模拟粒子，和带网织血小板模拟粒子的血小板模拟粒子。可以理解，本申请的发明思路在于，利用哺乳动物无核红细胞表面交联染料来模拟其它血细胞的荧光和体积性质，在该指引下，还可以模拟其它用于血液分析仪的血细胞，不仅限于网织红细胞模拟粒子和带网织血小板模拟粒子的血小板模拟粒子。
本申请的哺乳动物无核红细胞交联蛋白荧光染料分子，优选为，采用具有可供活化的羧基的蛋白荧光染料分子，对哺乳动物无核红细胞的细胞表面的可供活化的氨基进行交联，即氨基和羧基通过N-羟基琥珀酰亚胺交联。
同样的，本申请的血液分析仪用的细胞模拟粒子，其采用的蛋白荧光染料，优选为通式二、通式三、通式四和通式五所示结构的至少一种。更优选的，本申请所采用的哺乳动物无核红细胞还经过球形化处理。
由于采用以上技术方案，本申请的有益效果在于：
本申请的网织红细胞模拟粒子、血小板模拟粒子制备方法，采用N-羟基琥珀酰亚胺活化的蛋白荧光染料对不同体积大小的哺乳动物无核红细胞进行染色，从而分别获得网织红细胞模拟粒子和血小板模拟粒子。本申请制备的模拟粒子，其散点图荧光与体积方向接近新鲜血网织红细胞、网织血小板和血小板的散点图分布，既具备良好的稳定性，同时不干扰白细胞和有核红细胞通道的计数与分类。本申请的制备方法简单，便于加工，为网织红细胞模拟粒子和血小板模拟粒子提供了一种新的制备方法和途径。
含有本申请的网织红细胞模拟粒子和血小板模拟粒子的质控物，还可以与白细胞模拟粒子、有核红细胞模拟粒子和红细胞模拟粒子混合，制备融合质控物，实现了单支产品完成血液分析仪质控所需的全部检测参数监控与评价的目的，对质控物进行超过3个月的连续稳定性测试结果显示，本申请的质控物或校准物稳定性水平已达到国际一流产品水平。
附图说明
图1是本申请实施例中模拟粒子的制备流程图；
图2是本申请实施例中荧光染料A制备的网织红细胞模拟粒子和含网织血小板的血小板模拟粒子在迈瑞BC-6系列血细胞分析仪RET通道 检测得到的散点图，横坐标表示荧光强度，纵坐标表示前向散射光强度；
图3是本申请实施例中包括有荧光染料A制备的网织红细胞模拟粒子和含网织血小板的血小板模拟粒子在添加白细胞模拟粒子、有核红细胞模拟粒子、红细胞模拟粒子和保存液后制备的融合质控物的低中高三个水平的散点图，其中RET通道横坐标表示荧光强度，纵坐标表示前向散射光强度，Diff通道横坐标表示侧向散射光强度，纵坐标表示荧光强度，Baso通道横坐标表示侧向散射光强度，纵坐标表示前向散射光强度，NRBC通道横坐标表示荧光强度，纵坐标表示前向散射光强度；
图4是本申请实施例中制备的融合质控物低中高三个水平在2-8℃放置三个月后的散点图，其中RET通道横坐标表示荧光强度，纵坐标表示前向散射光强度，Diff通道横坐标表示侧向散射光强度，纵坐标表示荧光强度，Baso通道横坐标表示侧向散射光强度，纵坐标表示前向散射光强度，NRBC通道横坐标表示荧光强度，纵坐标表示前向散射光强度；
图5是本申请实施例中荧光染料B制备的网织红细胞模拟粒子和含网织血小板的血小板模拟粒子在迈瑞BC-6系列血细胞分析仪RET通道检测得到的散点图，横坐标表示荧光强度，纵坐标表示前向散射光强度；
图6是本申请实施例中包括有荧光染料B制备的网织红细胞模拟粒子和含网织血小板的血小板模拟粒子在添加白细胞模拟粒子、有核红细胞模拟粒子、红细胞模拟粒子和保存液后制备的融合质控物中值的散点图，其中RET通道横坐标表示荧光强度，纵坐标表示前向散射光强度，Diff通道横坐标表示侧向散射光强度，纵坐标表示荧光强度，Baso通道横坐标表示侧向散射光强度，纵坐标表示前向散射光强度，NRBC通道横坐标表示荧光强度，纵坐标表示前向散射光强度；
图7是本申请实施例中荧光染料C制备的网织红细胞模拟粒子和含网织血小板的血小板模拟粒子在迈瑞BC-6系列血细胞分析仪RET通道检测得到的散点图，横坐标表示荧光强度，纵坐标表示前向散射光强度；
图8是本申请实施例中包括有荧光染料C制备的网织红细胞模拟粒子和含网织血小板的血小板模拟粒子在添加白细胞模拟粒子、有核红细胞模拟粒子、红细胞模拟粒子和保存液后制备的融合质控物中值的散点图，其中RET通道横坐标表示荧光强度，纵坐标表示前向散射光强度，Diff通道横坐标表示侧向散射光强度，纵坐标表示荧光强度，Baso通道横坐标表示侧向散射光强度，纵坐标表示前向散射光强度，NRBC通道横坐标表示荧光强度，纵坐标表示前向散射光强度；
图9是本申请实施例中荧光染料D制备的网织红细胞模拟粒子和含网织血小板的血小板模拟粒子在迈瑞BC-6系列血细胞分析仪RET通道 检测得到的散点图，横坐标表示荧光强度，纵坐标表示前向散射光强度；
图10是本申请实施例中包括有荧光染料D制备的网织红细胞模拟粒子和含网织血小板的血小板模拟粒子在添加白细胞模拟粒子、有核红细胞模拟粒子、红细胞模拟粒子和保存液后制备的融合质控物中值的散点图，其中RET通道横坐标表示荧光强度，纵坐标表示前向散射光强度，Diff通道横坐标表示侧向散射光强度，纵坐标表示荧光强度，Baso通道横坐标表示侧向散射光强度，纵坐标表示前向散射光强度，NRBC通道横坐标表示荧光强度，纵坐标表示前向散射光强度；
图11是本申请实施例中荧光染料E制备的网织红细胞模拟粒子和含网织血小板的血小板模拟粒子在迈瑞BC-6系列血细胞分析仪RET通道检测得到的散点图，横坐标表示荧光强度，纵坐标表示前向散射光强度；
图12是本申请实施例中包括有荧光染料E制备的网织红细胞模拟粒子和含网织血小板的血小板模拟粒子在添加白细胞模拟粒子、有核红细胞模拟粒子、红细胞模拟粒子和保存液后制备的融合质控物中值的散点图，其中RET通道横坐标表示荧光强度，纵坐标表示前向散射光强度，Diff通道横坐标表示侧向散射光强度，纵坐标表示荧光强度，Baso通道横坐标表示侧向散射光强度，纵坐标表示前向散射光强度，NRBC通道横坐标表示荧光强度，纵坐标表示前向散射光强度；
图13是本申请实施例中荧光染料F制备的网织红细胞模拟粒子和含网织血小板的血小板模拟粒子在迈瑞BC-6系列血细胞分析仪RET通道检测得到的散点图，横坐标表示荧光强度，纵坐标表示前向散射光强度；
图14是本申请实施例中包括有荧光染料F制备的网织红细胞模拟粒子和含网织血小板的血小板模拟粒子在添加白细胞模拟粒子、有核红细胞模拟粒子、红细胞模拟粒子和保存液后制备的融合质控物中值的散点图，其中RET通道横坐标表示荧光强度，纵坐标表示前向散射光强度，Diff通道横坐标表示侧向散射光强度，纵坐标表示荧光强度，Baso通道横坐标表示侧向散射光强度，纵坐标表示前向散射光强度，NRBC通道横坐标表示荧光强度，纵坐标表示前向散射光强度；
图15是本申请实施例中荧光染料G制备的网织红细胞模拟粒子和含网织血小板的血小板模拟粒子在迈瑞BC-6系列血细胞分析仪RET通道检测得到的散点图，横坐标表示荧光强度，纵坐标表示前向散射光强度；
图16是本申请实施例中包括有荧光染料G制备的网织红细胞模拟 粒子和含网织血小板的血小板模拟粒子在添加白细胞模拟粒子、有核红细胞模拟粒子、红细胞模拟粒子和保存液后制备的融合质控物中值的散点图，其中RET通道横坐标表示荧光强度，纵坐标表示前向散射光强度，Diff通道横坐标表示侧向散射光强度，纵坐标表示荧光强度，Baso通道横坐标表示侧向散射光强度，纵坐标表示前向散射光强度，NRBC通道横坐标表示荧光强度，纵坐标表示前向散射光强度；
图17是本申请实施例中荧光染料H制备的网织红细胞模拟粒子和含网织血小板的血小板模拟粒子在迈瑞BC-6系列血细胞分析仪RET通道检测得到的散点图，横坐标表示荧光强度，纵坐标表示前向散射光强度；
图18是本申请实施例中包括有荧光染料H制备的网织红细胞模拟粒子和含网织血小板的血小板模拟粒子在添加白细胞模拟粒子、有核红细胞模拟粒子、红细胞模拟粒子和保存液后制备的融合质控物中值的散点图，其中RET通道横坐标表示荧光强度，纵坐标表示前向散射光强度，Diff通道横坐标表示侧向散射光强度，纵坐标表示荧光强度，Baso通道横坐标表示侧向散射光强度，纵坐标表示前向散射光强度，NRBC通道横坐标表示荧光强度，纵坐标表示前向散射光强度；
图2-图18中：1为网织红细胞、2为血小板、3为网织血小板、4为红细胞、5为淋巴细胞、6为单核细胞、7为中性粒细胞、8为嗜酸性粒细胞、9为嗜碱性粒细胞、10为有核红细胞。
具体实施方式
本申请中的蛋白荧光染料，是指在生物技术领域中，使蛋白质染色的荧光染料。
本申请在对无核红细胞进行蛋白荧光染料染色的研究中发现，对具有羧基的蛋白荧光染料使用N-羟基琥珀酰亚胺活化羧基后，与无核红细胞一起孵育，不仅无核红细胞的细胞膜不会被破坏，而且还会与细胞膜形成稳定的结合，使得原本没有荧光的无核红细胞会在激光的照射下产生荧光，使无核红细胞可以作为原料用于制备一些具有在检测中需要产生荧光的血液质控物；并且，不同体积大小的哺乳动物无核红细胞，可以分别制备出网织红细胞模拟粒子和含网织血小板的血小板模拟粒子。其中适用于本申请的蛋白荧光染料，其N-羟基琥珀酰亚胺化后的通式，如通式一所示；优选的，蛋白荧光染料为通式二、通式三、通式四和通式五所示结构的至少一种；更优选的为本申请所记载的荧光染料A-H中 的至少一种。
与采用塑料粒子或脂质体交联染料来模拟细胞的方法相比，本申请采用无核红细胞为原料，制备的模拟粒子具有与网织红细胞模拟粒子、网织血小板类似的膜性质，能够满足溶血和非溶血的检测通道的质控需求；本申请制备的模拟粒子既具备良好的稳定性，同时不影响其它细胞粒子的计数与分类。并且，本申请的制备方法如图1所示，只需要对无核红细胞进行染色、固定以及调节计数保存即可，工艺相对简单，便于加工。
下面通过具体实施例和附图对本申请作进一步详细说明。以下实施例仅对本申请进行进一步说明，不应理解为对本申请的限制。
除非特别说明，实施例中使用到的仪器、设备和溶液均为常规选择。实施例中，血细胞分析仪为迈瑞BC-6系列血细胞分析仪。
实施例一
本例对荧光染料A进行N-羟基琥珀酰亚胺活化，并溶解于有机溶剂中，制备成为荧光染料A母液。本例中活化的染料具体合成步骤为：在二氯甲烷中加入染料A、N-羟基琥珀酰亚胺(NHS)和1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐(EDC)，常温搅拌反应1小时即可制得，活化后的染料A。在其他实施例中，根据染料不同，也可以使用其他有机溶剂，例如甲醇。反应条件可以根据本领域常规技术手段做调整。
本例的保存液为市售常规使用的保存液，以下实施例与本例相同。
网织红细胞模拟粒子制备方法如下：
1、取人源红细胞，全血过滤，收集滤后红细胞(缩写RBC)；
2、洗涤液Ⅰ离心洗涤RBC两次；其中，洗涤液Ⅰ为含磷酸氢二钠2.0g/L、磷酸二氢钠0.2g/L和氯化钠9.0g/L的溶液；
3、洗涤液Ⅰ悬浮细胞沉淀，加入荧光染料A母液，使荧光染料终浓度为100mg/L，荧光染料加入细胞沉淀表层静置3分钟，使荧光染料与细胞充分接触，然后混匀，反应结束后，离心去上清，加入4倍体积的洗涤液Ⅱ，离心去上清；洗涤液Ⅱ为含柠檬酸钠35g/L和柠檬酸0.2g/L的溶液；
4、洗涤液Ⅱ悬浮细胞沉淀，加入37-40％甲醛固定剂，使其终浓度 为0.1％，室温处理2小时；固定结束后，洗涤液Ⅱ调节RBC至适当浓度，离心去上清，重复洗涤两次；
5、除去上清，保存液悬浮至RBC计数至适当浓度，获得网织红细胞模拟粒子；将模拟粒子于2～8℃冷藏，每24小时更换一次上清保存液，更换3次后，制备得到的网织红细胞模拟粒子可于保存液中长期保存。
血小板模拟粒子制备方法如下：
1、取山羊血原材料，全血过滤，收集滤后羊源红细胞(缩写RBC)；
2、洗涤液Ⅰ离心洗涤羊源RBC两次；其中，洗涤液Ⅰ为含磷酸氢二钠1.44g/L、磷酸二氢钾0.27g/L、氯化钠8g/L和氯化钾0.2g/L溶液；
3、洗涤液Ⅰ悬浮细胞沉淀，加入荧光染料A母液，使荧光染料终浓度为50mg/L，加入后迅速混匀；室温标记1小时，期间混匀3-4次，使荧光染料与细胞充分接触，反应结束后加入等体积洗涤液Ⅱ稀释，离心去上清，洗涤液Ⅱ重复洗涤1次；洗涤液Ⅱ为含柠檬酸钠35g/L、柠檬酸0.2g/L的溶液；
4、洗涤液Ⅱ悬浮细胞沉淀，加入37-40％甲醛固定剂，使其终浓度为0.5％，室温处理2小时；
5、固定结束后，使用牛血清白蛋白(缩写BSA)终浓度为0.05％的洗涤液Ⅱ等体积稀释，离心去上清，重复洗涤2次；
6、保存液悬浮至PLT计数至适当浓度，2～8℃冷藏，含网织血小板的血小板模拟粒子制备完成。
融合质控物调配：
添加白细胞模拟粒子、红细胞模拟粒子、有核红细胞模拟粒子至本例制备的网织红细胞模拟粒子和含网织血小板的血小板模拟粒子中，按比例混合，形成质控物，各组分浓度如下：
低值：白细胞模拟粒子2.8×109/L，红细胞模拟粒子2.8×1012/L，血小板模拟粒子75×109/L，网织红细胞模拟粒子0.02×1012/L，有核红细胞模拟粒子0.11×109/L。
中值：白细胞模拟粒子8.5×109/L，红细胞模拟粒子4.5×1012/L，血小板模拟粒子225×109/L，网织红细胞模拟粒子0.11×1012/L，有核红细胞模拟粒子0.35×109/L。
高值：白细胞模拟粒子20×109/L，红细胞模拟粒子5.2×1012/L，血小板模拟粒子490×109/L，网织红细胞模拟粒子0.26×1012/L，有核红细 胞模拟粒子0.8×109/L。
用以荧光染色为检测原理的血液细胞分析仪分别对本例制备的网织红细胞模拟粒子、血小板模拟粒子和质控物进行检测。网织红细胞模拟粒子和血小板模拟粒子的散点图如图2所示，其中左图为网织红细胞模拟粒子的散点图，右图为血小板模拟粒子的散点图，图中，1为网织红细胞、2为血小板、3为网织血小板；融合质控物低、中、高值的散点图如图3所示，图中，第一行为融合质控物低值散点图、第二行为中值散点图、第三行为高值散点图，1为网织红细胞、2为血小板、3为网织血小板、4为红细胞、5为淋巴细胞、6为单核细胞、7为中性粒细胞、8为嗜酸性粒细胞、9为嗜碱性粒细胞、10为有核红细胞。图2的结果显示，本例制备的网织红细胞模拟粒子和血小板模拟粒子具有新鲜血网织红细胞和血小板的散点图分布，在血小板模拟粒子的散点图中，其血小板2的右上方部分即网织血小板3；图3的结果显示，本例制备的网织红细胞模拟粒子和血小板模拟粒子，不干扰白细胞、有核红细胞等其它粒子通道的计数与分类，能够用于制备血液质控物或校准物。
实施例二
对荧光染料B进行N-羟基琥珀酰亚胺活化，并溶解于有机溶剂中，制备成为荧光染料B母液。
网织红细胞模拟粒子制备：
1、取人源红细胞，全血过滤，收集滤后RBC；
2、洗涤液Ⅰ离心洗涤RBC两次，洗涤液Ⅰ为含磷酸氢二钾1.41g/L、磷酸二氢钾0.27g/L和氯化钾11.8g/L的溶液；
3、加入重铬酸钾溶液悬浮细胞沉淀，重铬酸钾的终浓度为0.1g/L，并加入50％戊二醛固定剂，使其终浓度为0.005％，室温固定2小时，固定结束后，洗涤液Ⅰ离心洗涤RBC两次；
4、洗涤液Ⅱ悬浮细胞沉淀，加入荧光染料B母液，使荧光染料终浓度为50mg/L，加入后迅速混匀；室温标记2小时，期间混匀3-4次，使荧光染料与细胞充分接触，反应结束后加入4倍体积的洗涤液Ⅱ，离心去上清，洗涤液Ⅱ重复洗涤1次；洗涤液Ⅱ为含柠檬酸钠17g/L、柠檬酸0.1g/L和氯化钠5g/L的溶液；
5、除去上清，保存液悬浮至RBC计数至适当浓度，获得网织红细 胞模拟粒子。将模拟粒子于2～8℃冷藏，每24小时更换一次上清保存液，更换3次后，制备得到的网织红细胞模拟粒子可于保存液中长期保存。
血小板模拟粒子制备：
1、取山羊血原材料，全血过滤，收集滤后羊源RBC；
2、洗涤液Ⅰ离心洗涤2次；洗涤液Ⅰ为含磷酸氢二钠2.0g/L、磷酸二氢钠0.2g/L和氯化钠9.0g/L的溶液；
3、洗涤液Ⅰ悬浮细胞沉淀，加入荧光染料B母液，使荧光染料终浓度为5mg/L，加入后迅速混匀；室温标记15分钟，期间混匀3-4次，使荧光染料与细胞充分接触，反应结束后加入等体积洗涤液Ⅱ稀释，离心去上清，重复洗涤2次；洗涤液Ⅱ为含柠檬酸钠17g/L、柠檬酸0.1g/L和氯化钠5g/L的溶液；
4、洗涤液Ⅱ悬浮细胞沉淀，加入50％戊二醛固定剂，使其终浓度为0.005％，以及37-40％甲醛固定剂，使其终浓度为0.1％，室温处理过夜；
5、固定结束后，使用BSA终浓度为0.025％的洗涤液Ⅱ等体积稀释，离心去上清，重复洗涤2次；
6、保存液悬浮至PLT计数至适当浓度，2～8℃冷藏，含网织血小板的血小板模拟粒子制备完成。
融合质控物调配：
添加白细胞模拟粒子、红细胞模拟粒子、有核红细胞模拟粒子至本例制备的网织红细胞模拟粒子和血小板模拟粒子中，按比例混合，形成融合质控物，使得：
中值：白细胞模拟粒子8.5×109/L，红细胞模拟粒子4.5×1012/L，血小板模拟粒子225×109/L，网织红细胞模拟粒子0.11×1012/L，有核红细胞模拟粒子0.35×109/L。
用以荧光染色为检测原理的血液细胞分析仪分别对本例制备的网织红细胞模拟粒子、血小板模拟粒子和质控物进行检测。网织红细胞模拟粒子和血小板模拟粒子的散点图如图5所示，其中左图为网织红细胞模拟粒子的散点图，右图为血小板模拟粒子的散点图，图中，1为网织红细胞、2为血小板、3为网织血小板；融合质控物中值散点图如图6所示，图中，1为网织红细胞、2为血小板、3为网织血小板、4为红细胞、5为淋巴细胞、6为单核细胞、7为中性粒细胞、8为嗜酸性粒细胞、9为 嗜碱性粒细胞、10为有核红细胞。图5的结果显示，本例制备的网织红细胞模拟粒子和血小板模拟粒子具有新鲜血网织红细胞和血小板的散点图分布，在血小板模拟粒子的散点图中，其血小板2的右上方部分即网织血小板3；图6的结果显示，本例制备的网织红细胞模拟粒子和血小板模拟粒子，不干扰白细胞、有核红细胞等其它粒子通道的计数与分类，能够用于制备血液质控物或校准物。
实施例三
对荧光染料C进行N-羟基琥珀酰亚胺活化，并溶解于有机溶剂中，制备成为荧光染料C母液。
网织红细胞模拟粒子制备：
1、取人源红细胞，全血过滤，收集滤后RBC；
2、洗涤液Ⅰ离心洗涤RBC两次；洗涤液Ⅰ为含磷酸氢二钠1.44g/L、磷酸二氢钾0.27g/L、氯化钠8g/L和氯化钾0.2g/L的溶液；
3、洗涤液Ⅰ悬浮细胞沉淀，加入荧光染料C母液，使荧光染料终浓度为10mg/L，加入后迅速混匀；室温标记20分钟，期间混匀3-4次，使荧光染料与细胞充分接触，反应结束后加入4倍体积的洗涤液Ⅱ，离心去上清，重复洗涤1次；洗涤液Ⅱ为含柠檬酸钠17g/L、柠檬酸0.1g/L和氯化钠5g/L的溶液；
4、洗涤液Ⅱ悬浮细胞沉淀，加入50％戊二醛，使其终浓度为0.05％，室温处理2小时；固定结束后，使用BSA终浓度为1％的洗涤液Ⅱ调节RBC计数至适当浓度，离心去上清，重复洗涤2次；
5、保存液悬浮至RBC计数至适当浓度，获得本例的网织红细胞模拟粒子。
血小板模拟粒子制备：
1、取山羊血原材料，全血过滤，收集滤后羊源RBC；
2、洗涤液Ⅰ离心洗涤2次；洗涤液Ⅰ为含磷酸氢二钠2.0g/L、磷酸二氢钠0.2g/L和氯化钠9.0g/L的溶液；
3、洗涤液Ⅰ悬浮细胞沉淀，加入一定量荧光染料C母液，使荧光染料终浓度为5mg/L，加入后迅速混匀。室温标记15分钟，期间混匀3-4次，使荧光染料与细胞充分接触，反应结束后加入等体积洗涤液Ⅱ稀释，离心去上清，重复洗涤1次；洗涤液Ⅱ为含柠檬酸钠17g/L、柠 檬酸0.1g/L和氯化钠5g/L的溶液；
4、洗涤液Ⅱ悬浮细胞沉淀，加入37-40％甲醛固定剂，使其终浓度为0.25％，室温处理4H；
5、固定结束后，使用BSA终浓度为0.05％的洗涤液Ⅱ等体积稀释，离心去上清，重复洗涤2次；
6、保存液悬浮至PLT计数至适当浓度，2～8℃冷藏，含网织血小板的血小板模拟粒子制备完成。
融合质控物调配：
添加白细胞模拟粒子、红细胞模拟粒子、有核红细胞模拟粒子至本例制备的网织红细胞模拟粒子和血小板模拟粒子中，按比例混合，形成融合质控物，使得：
中值：白细胞模拟粒子8.5×109/L，红细胞模拟粒子4.5×1012/L，血小板模拟粒子225×109/L，网织红细胞模拟粒子0.11×1012/L，有核红细胞模拟粒子0.35×109/L。
用以荧光染色为检测原理的血液细胞分析仪分别对本例制备的网织红细胞模拟粒子、血小板模拟粒子和质控物进行检测。网织红细胞模拟粒子和血小板模拟粒子的散点图如图7所示，其中左图为网织红细胞模拟粒子的散点图，右图为血小板模拟粒子的散点图，图中，1为网织红细胞、2为血小板、3为网织血小板；融合质控物中值散点图如图8所示，图中，1为网织红细胞、2为血小板、3为网织血小板、4为红细胞、5为淋巴细胞、6为单核细胞、7为中性粒细胞、8为嗜酸性粒细胞、9为嗜碱性粒细胞、10为有核红细胞。图7的结果显示，本例制备的网织红细胞模拟粒子和血小板模拟粒子具有新鲜血网织红细胞和血小板的散点图分布，在血小板模拟粒子的散点图中，其血小板2的右边部分即网织血小板3；图8的结果显示，本例制备的网织红细胞模拟粒子和血小板模拟粒子，不干扰白细胞、有核红细胞等其它粒子通道的计数与分类，能够用于制备血液质控物或校准物。
实施例四
对荧光染料D进行N-羟基琥珀酰亚胺活化，并溶解于有机溶剂中，制备成为荧光染料D母液。
网织红细胞模拟粒子制备：
1、取人源红细胞，全血过滤，收集滤后RBC；
2、洗涤液Ⅰ离心洗涤RBC 2次；洗涤液Ⅰ为含有磷酸氢二钠1.44g/L、磷酸二氢钾0.27g/L、氯化钠8g/L和氯化钾0.2g/L的溶液；
3、洗涤液Ⅰ悬浮细胞沉淀，加入荧光染料D母液，使荧光染料终浓度为40mg/L，加入后迅速混匀；2～8℃标记30分钟，期间混匀1-2次，使荧光染料与细胞充分接触，反应结束后加入4倍体积的洗涤液Ⅱ，离心去上清，重复洗涤1次；洗涤液Ⅱ为含柠檬酸钠17g/L、柠檬酸0.1g/L和氯化钠5g/L的溶液；
4、洗涤液Ⅱ悬浮细胞沉淀，加入50％戊二醛，使其终浓度为0.05％，室温过夜；固定结束后，使用BSA终浓度为1％的洗涤液Ⅱ调节RBC计数至适当浓度，离心去上清，重复洗涤2次；
5、保存液悬浮至RBC计数至适当浓度，获得网织红细胞模拟粒子。
血小板模拟粒子制备：
1、取山羊血原材料，全血过滤，收集滤后羊源RBC；
2、洗涤液Ⅰ离心洗涤羊源RBC两次；洗涤液Ⅰ为含磷酸氢二钠1.44g/L、磷酸二氢钾0.27g/L、氯化钠8g/L和氯化钾0.2g/L的溶液；
3、洗涤液Ⅰ悬浮细胞沉淀，加入一定量荧光染料D母液，使荧光染料终浓度为20mg/L，加入后迅速混匀；室温标记1小时，期间混匀3-4次，使荧光染料与细胞充分接触，反应结束后加入等体积洗涤液Ⅱ稀释，离心去上清，重复洗涤2次；洗涤液Ⅱ为含柠檬酸钠35g/L和柠檬酸0.2g/L的溶液；
4、洗涤液Ⅱ悬浮细胞沉淀，加入50％戊二醛固定剂，使其终浓度为0.03％，以及37-40％甲醛固定剂，使其终浓度为0.15％，室温处理8小时；
5、固定结束后，使用BSA终浓度为0.15％的洗涤液Ⅱ等体积稀释，离心去上清，重复洗涤2次；
6、保存液悬浮至PLT计数至适当浓度，2～8℃冷藏，含网织血小板的血小板模拟粒子制备完成。
融合质控物调配：
添加白细胞模拟粒子、红细胞模拟粒子、有核红细胞模拟粒子至本例的网织红细胞模拟粒子和血小板模拟粒子中，按比例混合，形成融合质控物，使得：
中值：白细胞模拟粒子8.5×109/L，红细胞模拟粒子4.5×1012/L，血小板模拟粒子225×109/L，网织红细胞模拟粒子0.11×1012/L，有核红细胞模拟粒子0.35×109/L。
用以荧光染色为检测原理的血液细胞分析仪分别对本例制备的网织红细胞模拟粒子、血小板模拟粒子和质控物进行检测。网织红细胞模拟粒子和血小板模拟粒子的散点图如图9所示，其中左图为网织红细胞模拟粒子的散点图，右图为血小板模拟粒子的散点图，图中，1为网织红细胞、2为血小板、3为网织血小板；融合质控物中值散点图如图10所示，图中，1为网织红细胞、2为血小板、3为网织血小板、4为红细胞、5为淋巴细胞、6为单核细胞、7为中性粒细胞、8为嗜酸性粒细胞、9为嗜碱性粒细胞、10为有核红细胞。图9的结果显示，本例制备的网织红细胞模拟粒子和血小板模拟粒子具有新鲜血网织红细胞和血小板的散点图分布，在血小板模拟粒子的散点图中，其血小板2的右边部分即网织血小板3；图10的结果显示，本例制备的网织红细胞模拟粒子和血小板模拟粒子，不干扰白细胞、有核红细胞等其它粒子通道的计数与分类，能够用于制备血液质控物或校准物。
实施例五
对荧光染料E进行N-羟基琥珀酰亚胺活化，并溶解于有机溶剂中，制备成为荧光染料E母液。
网织红细胞模拟粒子制备：
1、取人源红细胞，全血过滤，收集滤后RBC；
2、洗涤液Ⅰ离心洗涤RBC两次；洗涤液Ⅰ为含磷酸氢二钠1.44g/L、磷酸二氢钾0.27g/L、氯化钠8g/L和氯化钾0.2g/L的溶液；
3、洗涤液Ⅰ悬浮细胞沉淀，加入荧光染料E母液，使荧光染料终浓度为15mg/L，加入后迅速混匀；室温标记30分钟，期间混匀3-4次，使荧光染料与细胞充分接触，反应结束后加入4倍体积的洗涤液Ⅰ，离心去上清，重复洗涤1次；
4、洗涤液Ⅱ悬浮细胞沉淀，加入37-40％甲醛固定剂，使其终浓度为0.1％，室温处理1小时；固定结束后，使用BSA终浓度为0.5％的洗涤液Ⅱ调节RBC计数至适当浓度，离心去上清，重复洗涤2次；洗涤液Ⅱ为含柠檬酸钠17g/L、柠檬酸0.1g/L和氯化钠5g/L的溶液；
5、保存液悬浮至RBC计数至适当浓度，获得网织红细胞模拟粒子。
血小板模拟粒子的制备：
1、取山羊血原材料，全血过滤，收集滤后羊源RBC；
2、洗涤液Ⅰ离心洗涤2次；洗涤液Ⅰ为含磷酸氢二钠2.0g/L、磷酸二氢钠0.2g/L和氯化钠9.0g/L的溶液；
3、洗涤液Ⅰ悬浮细胞沉淀，加入荧光染料E母液，使荧光染料终浓度为10mg/L，加入后迅速混匀；室温标记1小时，期间混匀3-4次，使荧光染料与细胞充分接触，反应结束后加入4倍体积洗涤液Ⅱ稀释，离心去上清，重复洗涤1次；洗涤液Ⅱ为含柠檬酸钠17g/L、柠檬酸0.1g/L和氯化钠5g/L的溶液；
4、洗涤液Ⅱ悬浮细胞沉淀，加入37-40％甲醛固定剂，使其终浓度为0.8％，室温处理过夜；
5、固定结束后，使用BSA终浓度为0.05％的洗涤液Ⅱ等体积稀释，离心去上清，重复洗涤2次；
6、保存液悬浮至PLT计数至适当浓度，2～8℃冷藏，含网织血小板的血小板模拟粒子制备完成。
融合质控物调配：
添加白细胞模拟粒子、红细胞模拟粒子、有核红细胞模拟粒子至本例的网织红细胞模拟粒子和血小板模拟粒子中，按比例混合，形成融合质控物，使得：
中值：白细胞模拟粒子8.5×109/L，红细胞模拟粒子4.5×1012/L，血小板模拟粒子225×109/L，网织红细胞模拟粒子0.11×1012/L，有核红细胞模拟粒子0.35×109/L。
用以荧光染色为检测原理的血液细胞分析仪分别对本例制备的网织红细胞模拟粒子、血小板模拟粒子和质控物进行检测。网织红细胞模拟粒子和血小板模拟粒子的散点图如图11所示，其中左图为网织红细胞模拟粒子的散点图，右图为血小板模拟粒子的散点图，图中，1为网织红细胞、2为血小板、3为网织血小板；融合质控物中值散点图如图12所示，图中，1为网织红细胞、2为血小板、3为网织血小板、4为红细胞、5为淋巴细胞、6为单核细胞、7为中性粒细胞、8为嗜酸性粒细胞、9为嗜碱性粒细胞、10为有核红细胞。图11的结果显示，本例制备的网织红细胞模拟粒子和血小板模拟粒子具有新鲜血网织红细胞和血小板的 散点图分布，在血小板模拟粒子的散点图中，其血小板2的右边部分即网织血小板3；图12的结果显示，本例制备的网织红细胞模拟粒子和血小板模拟粒子，不干扰白细胞、有核红细胞等其它粒子通道的计数与分类，能够用于制备血液质控物或校准物。
实施例六
对荧光染料F进行N-羟基琥珀酰亚胺活化，并溶解于有机溶剂中，制备成为荧光染料F母液。
网织红细胞模拟粒子的制备：
1、取人源红细胞，全血过滤，收集滤后RBC；
2、洗涤液Ⅰ离心洗涤RBC两次；洗涤液Ⅰ为含磷酸氢二钠1.44g/L、磷酸二氢钾0.27g/L、氯化钠8g/L和氯化钾0.2g/L的溶液；
3、洗涤液Ⅰ悬浮细胞沉淀，加入荧光染料F母液，使荧光染料终浓度为55mg/L，缓慢加入细胞表层静置，5分钟后混匀，2～8℃标记30分钟，使荧光染料与细胞充分接触，反应结束后加入4倍体积的洗涤液Ⅱ，离心去上清，重复洗涤1次；洗涤液Ⅱ为含柠檬酸钠17g/L、柠檬酸0.1g/L和氯化钠5g/L的溶液；
4、洗涤液Ⅱ悬浮细胞沉淀，加入50％戊二醛，使其终浓度为0.05％，室温处理3小时。固定结束后，使用BSA终浓度为0.6％的洗涤液Ⅱ调节RBC计数至适当浓度，离心去上清，重复洗涤2次；
5、保存液悬浮至RBC计数至适当浓度，获得网织红细胞模拟粒子。
血小板模拟粒子的制备：
1、取山羊血原材料，全血过滤，收集滤后羊源RBC；
2、洗涤液Ⅰ离心洗涤2次；洗涤液Ⅰ为含磷酸氢二钠2.0g/L、磷酸二氢钠0.2g/L和氯化钠9.0g/L的溶液；
3、洗涤液Ⅰ悬浮细胞沉淀，加入荧光染料F母液，使荧光染料终浓度为15mg/L，缓慢加入细胞表层静置，8分钟后混匀，室温标记15分钟，期间混匀3-4次，使荧光染料与细胞充分接触，反应结束后加入4倍体积洗涤液Ⅱ稀释，离心去上清，重复洗涤1次；洗涤液Ⅱ为含柠檬酸钠17g/L、柠檬酸0.1g/L和氯化钠5g/L的溶液；
4、洗涤液Ⅱ悬浮细胞沉淀，加入戊二醛固定剂，使其终浓度为0.015％，室温处理过夜。
5、固定结束后，使用BSA终浓度为0.025％的洗涤液Ⅱ等体积稀释，离心去上清，重复洗涤2次；
6、保存液悬浮至PLT计数至适当浓度，2～8℃冷藏，含网织血小板的血小板模拟粒子制备完成。
融合质控物调配：
添加白细胞模拟粒子、红细胞模拟粒子、有核红细胞模拟粒子至本例的网织红细胞模拟粒子和血小板模拟粒子中，按比例混合，形成融合质控物，使得：
中值：白细胞模拟粒子8.5×109/L，红细胞模拟粒子4.5×1012/L，血小板模拟粒子225×109/L，网织红细胞模拟粒子0.11×1012/L，有核红细胞模拟粒子0.35×109/L。
用以荧光染色为检测原理的血液细胞分析仪分别对本例制备的网织红细胞模拟粒子、血小板模拟粒子和质控物进行检测。网织红细胞模拟粒子和血小板模拟粒子的散点图如图13所示，其中左图为网织红细胞模拟粒子的散点图，右图为血小板模拟粒子的散点图，图中，1为网织红细胞、2为血小板、3为网织血小板；融合质控物中值散点图如图14所示，图中，1为网织红细胞、2为血小板、3为网织血小板、4为红细胞、5为淋巴细胞、6为单核细胞、7为中性粒细胞、8为嗜酸性粒细胞、9为嗜碱性粒细胞、10为有核红细胞。图13的结果显示，本例制备的网织红细胞模拟粒子和血小板模拟粒子具有新鲜血网织红细胞和血小板的散点图分布，在血小板模拟粒子的散点图中，其血小板2的右边部分即网织血小板3；图14的结果显示，本例制备的网织红细胞模拟粒子和血小板模拟粒子，不干扰白细胞、有核红细胞等其它粒子通道的计数与分类，能够用于制备血液质控物或校准物。
实施例七
对荧光染料G进行N-羟基琥珀酰亚胺活化，并溶解于有机溶剂中，制备成为荧光染料G母液。
网织红细胞模拟粒子的制备：
1、取人源红细胞，全血过滤，收集滤后RBC；
2、洗涤液Ⅰ离心洗涤RBC两次；洗涤液Ⅰ为含磷酸氢二钠1.44g/L、磷酸二氢钾0.27g/L、氯化钠8g/L和氯化钾0.2g/L的溶液；
3、洗涤液Ⅰ悬浮细胞沉淀，加入荧光染料G母液，使荧光染料终浓度为85mg/L，加入后迅速混匀；2～8℃标记45分钟，期间混匀1-2次，使荧光染料与细胞充分接触，反应结束后加入4倍体积的洗涤液Ⅱ，离心去上清，重复洗涤1次；洗涤液Ⅱ为含柠檬酸钠17g/L、柠檬酸0.1g/L和氯化钠5g/L的溶液；
4、洗涤液Ⅱ悬浮细胞沉淀，加入50％戊二醛，使其终浓度为0.1％，室温处理1小时；固定结束后，使用BSA终浓度为1％的洗涤液Ⅱ调节RBC计数至适当浓度，离心去上清，重复洗涤2次；
5、保存液悬浮至RBC计数至适当浓度，获得网织红细胞模拟粒子。
血小板模拟粒子的制备：
1、取山羊血原材料，全血过滤，收集滤后羊源RBC；
2、洗涤液Ⅰ离心洗涤羊源RBC两次；洗涤液Ⅰ为含磷酸氢二钠1.44g/L、磷酸二氢钾0.27g/L、氯化钠8g/L和氯化钾0.2g/L的溶液；
3、洗涤液Ⅰ悬浮细胞沉淀，加入一定量荧光染料G母液，使荧光染料终浓度为35mg/L，加入后缓慢混匀；室温标记30分钟，期间混匀3-4次，使荧光染料与细胞充分接触，反应结束后加入4等体积洗涤液Ⅱ稀释，离心去上清，重复洗涤1次；洗涤液Ⅱ为含柠檬酸钠17g/L、柠檬酸0.1g/L和氯化钠5g/L的溶液；
4、洗涤液Ⅱ悬浮细胞沉淀，加入37-40％甲醛固定剂，使其终浓度为0.3％，室温处理4小时；
5、固定结束后，使用BSA终浓度为0.05％的洗涤液Ⅱ等体积稀释，离心去上清，重复洗涤2次；
6、保存液悬浮至PLT计数至适当浓度，2～8℃冷藏，含网织血小板的血小板模拟粒子制备完成。
融合质控物调配：
添加白细胞模拟粒子、红细胞模拟粒子、有核红细胞模拟粒子至本例的网织红细胞模拟粒子和血小板模拟粒子中，按比例混合，形成融合质控物，使得：
中值：白细胞模拟粒子8.5×109/L，红细胞模拟粒子4.5×1012/L，血小板模拟粒子225×109/L，网织红细胞模拟粒子0.11×1012/L，有核红细胞模拟粒子0.35×109/L。
用以荧光染色为检测原理的血液细胞分析仪分别对本例制备的网织 红细胞模拟粒子、血小板模拟粒子和质控物进行检测。网织红细胞模拟粒子和血小板模拟粒子的散点图如图15所示，其中左图为网织红细胞模拟粒子的散点图，右图为血小板模拟粒子的散点图，图中，1为网织红细胞、2为血小板、3为网织血小板；融合质控物中值散点图如图16所示，图中，1为网织红细胞、2为血小板、3为网织血小板、4为红细胞、5为淋巴细胞、6为单核细胞、7为中性粒细胞、8为嗜酸性粒细胞、9为嗜碱性粒细胞、10为有核红细胞。图15的结果显示，本例制备的网织红细胞模拟粒子和血小板模拟粒子具有新鲜血网织红细胞和血小板的散点图分布，在血小板模拟粒子的散点图中，其血小板2的右边部分即网织血小板3；图16的结果显示，本例制备的网织红细胞模拟粒子和血小板模拟粒子，不干扰白细胞、有核红细胞等其它粒子通道的计数与分类，能够用于制备血液质控物或校准物。
实施例八
对荧光染料H进行N-羟基琥珀酰亚胺活化，并溶解于有机溶剂中，制备成为荧光染料H母液。
网织红细胞模拟粒子的制备：
1、取人源红细胞，全血过滤，收集滤后RBC；
2、洗涤液Ⅰ离心洗涤RBC两次；洗涤液Ⅰ为含磷酸氢二钠1.44g/L、磷酸二氢钾0.27g/L、氯化钠8g/L和氯化钾0.2g/L的溶液；
3、洗涤液Ⅰ悬浮细胞沉淀，加入一定量荧光染料H母液，使荧光染料终浓度为25mg/L，缓慢加入细胞表层静置，室温4分钟后混匀，室温标记20分钟，期间混匀1-2次，使荧光染料与细胞充分接触，反应结束后加入等倍体积的洗涤液Ⅰ，离心去上清，重复洗涤2次；
4、洗涤液Ⅱ悬浮细胞沉淀，加入37-40％甲醛固定剂，使其终浓度为0.5％，室温处理2小时；固定结束后，使用BSA终浓度为1％的洗涤液Ⅱ调节RBC计数至适当浓度，离心去上清，重复洗涤2次；洗涤液Ⅱ为含柠檬酸钠35g/L和柠檬酸0.2g/L的溶液；
5、保存液悬浮至RBC计数至适当浓度，获得网织红细胞模拟粒子。
血小板制备
1、取山羊血原材料，全血过滤，收集滤后羊源RBC；
2、洗涤液Ⅰ离心洗涤2次；洗涤液Ⅰ为含磷酸氢二钠2.0g/L、磷酸 二氢钠0.2g/L和氯化钠9.0g/L的溶液；
3、洗涤液Ⅰ悬浮细胞沉淀，加入一定量荧光染料H母液，使荧光染料终浓度为5mg/L，缓慢加入细胞表层静置，室温10分钟后混匀，室温标记15分钟，期间混匀1-2次，使荧光染料与细胞充分接触，反应结束后加入等体积洗涤液Ⅱ稀释，离心去上清，重复洗涤1次；洗涤液Ⅱ为含柠檬酸钠35g/L和柠檬酸0.2g/L的溶液；
4、洗涤液Ⅱ悬浮细胞沉淀，加入戊二醛固定剂，使其终浓度为0.05％，室温处理4小时；
5、固定结束后，使用BSA终浓度为0.04％的洗涤液Ⅱ等体积稀释，离心去上清，重复洗涤2次；
6、保存液悬浮至PLT计数至适当浓度，2～8℃冷藏，含网织血小板的血小板模拟粒子制备完成。
融合质控物调配：
添加白细胞模拟粒子、红细胞模拟粒子、有核红细胞模拟粒子至本例的网织红细胞模拟粒子和血小板模拟粒子中，按比例混合，形成融合质控物，使得：
中值：白细胞模拟粒子8.5×109/L，红细胞模拟粒子4.5×1012/L，血小板模拟粒子225×109/L，网织红细胞模拟粒子0.11×1012/L，有核红细胞模拟粒子0.35×109/L。
用以荧光染色为检测原理的血液细胞分析仪分别对本例制备的网织红细胞模拟粒子、血小板模拟粒子和质控物进行检测。网织红细胞模拟粒子和血小板模拟粒子的散点图如图17所示，其中左图为网织红细胞模拟粒子的散点图，右图为血小板模拟粒子的散点图，图中，1为网织红细胞、2为血小板、3为网织血小板；融合质控物中值散点图如图18所示，图中，1为网织红细胞、2为血小板、3为网织血小板、4为红细胞、5为淋巴细胞、6为单核细胞、7为中性粒细胞、8为嗜酸性粒细胞、9为嗜碱性粒细胞、10为有核红细胞。图17的结果显示，本例制备的网织红细胞模拟粒子和血小板模拟粒子具有新鲜血网织红细胞和血小板的散点图分布，在血小板模拟粒子的散点图中，其血小板2的右边部分即网织血小板3；图18的结果显示，本例制备的网织红细胞模拟粒子和血小板模拟粒子，不干扰白细胞、有核红细胞等其它粒子通道的计数与分类，能够用于制备血液质控物或校准物。
在以上试验的基础上，本申请将八个实施例的融合质控物2～8℃冷藏保存三个月，每周定期对质控物进行血液细胞分析仪检测，结果显示，本申请的质控物各通道的散点图都没有显著变化，其中，实施例1的融合质控物低中高值放置3个月后测定的散点图如图4所示，可见，本申请的质控物中各组分稳定性高，且和其他细胞的质控品混合也能保持各自的细胞模拟物性能稳定，不会相互影响。
以上内容是结合具体的实施方式对本申请所作的进一步详细说明，不能认定本申请的具体实施只局限于这些说明。对于本申请所属技术领域的普通技术人员来说，在不脱离本申请构思的前提下，还可以做出若干简单推演或替换，都应当视为属于本申请的保护范围。

Claims (19)

  1. 一种网织红细胞模拟粒子的制备方法，其特征在于：采用N-羟基琥珀酰亚胺活化的具有羧基的蛋白荧光染料，对哺乳动物无核红细胞进行染色，并对所述哺乳动物无核红细胞进行固定处理，制成网织红细胞模拟粒子；所述固定处理可以在染色前或染色后进行，所述哺乳动物无核红细胞的体积大小为60-120fL，所述哺乳动物无核红细胞优选为人源红细胞、兔红细胞、牛红细胞、猪红细胞、马红细胞或豚鼠红细胞。
  2. 一种血小板模拟粒子的制备方法，其特征在于：采用N-羟基琥珀酰亚胺活化的具有羧基的蛋白荧光染料，对哺乳动物无核红细胞进行染色，并对所述哺乳动物无核红细胞进行固定处理，制成血小板模拟粒子；所述固定处理可以在染色前或染色后进行，所述哺乳动物无核红细胞体积大小为2-25fL，所述哺乳动物无核红细胞优选为山羊源红细胞或绵羊红细胞。
  3. 根据权利要求1或2所述的制备方法，其特征在于：所述采用N-羟基琥珀酰亚胺活化的具有羧基的蛋白荧光染料，对哺乳动物无核红细胞进行染色，包括以下步骤，
    提取所述哺乳动物无核红细胞；
    提供经N-羟基琥珀酰亚胺活化的蛋白荧光染料，所述蛋白荧光染料中具有可供活化的羧基，所述羧基被N-羟基琥珀酰亚胺活化；
    将所述N-羟基琥珀酰亚胺活化的蛋白荧光染料与所述哺乳动物无核红细胞孵育，对所述哺乳动物无核红细胞进行染色，获得染色的红细胞。
  4. 根据权利要求1或2所述的制备方法，其特征在于：还包括对经过染色和固定的细胞进行洗涤。
  5. 根据权利要求1或2所述的制备方法，其特征在于：所述N-羟基琥珀酰亚胺活化的具有羧基的蛋白荧光染料为通式一所示结构，
    Figure PCTCN2017071755-appb-100001
    通式一中，R为蛋白荧光染料，n为1-4的整数，n值取决于所述蛋白荧光染料的羧基个数。
  6. 根据权利要求1或2所述的制备方法，其特征在于：所述蛋白荧光染料为通式二、通式三、通式四和通式五所示结构的至少一种，
    Figure PCTCN2017071755-appb-100002
    通式二至通式五中，m为0、1、2或3，R1、R2各自独立地选自磺酸基、卤素原子或者氢原子；
    R3和R4各自独立地选自烷基或含羧基的烷基，并且，R3和R4中至少有一个为含羧基的烷基；
    R5、R6各自独立地选自磺酸基、卤素原子、烷基或者氢原子。
  7. 根据权利要求1或2所述的制备方法，其特征在于：所述蛋白荧光染料为荧光染料A-H中的至少一种，
    荧光染料A的结构式为
    Figure PCTCN2017071755-appb-100003
    荧光染料B的结构式为
    Figure PCTCN2017071755-appb-100004
    荧光染料C的结构式为
    Figure PCTCN2017071755-appb-100005
    荧光染料D的结构式为
    Figure PCTCN2017071755-appb-100006
    荧光染料E的结构式为
    Figure PCTCN2017071755-appb-100007
    荧光染料F的结构式为
    Figure PCTCN2017071755-appb-100008
    荧光染料G的结构式为
    Figure PCTCN2017071755-appb-100009
    荧光染料H的结构式为
    Figure PCTCN2017071755-appb-100010
  8. 根据权利要求1或2所述的制备方法，其特征在于：所述固定处理采用的固定剂为重金属盐、甲醛、丙酮醛、戊二醛和多聚甲醛中的至少一种；
    优选的，所述甲醛、丙酮醛、戊二醛或多聚甲醛的反应浓度为体积比0.005％-1％；
    优选的，所述重金属盐为重铬酸盐，更优选为重铬酸钾或重铬酸。
  9. 根据权利要求1或2所述的制备方法，其特征在于：还包括对所述哺乳动物无核红细胞进行球形化处理。
  10. 根据权利要求1、3-9任一项所述的制备方法制备的网织红细胞模拟粒子。
  11. 根据权利要求2-9任一项所述的制备方法制备的血小板模拟粒子，其特征在于：所述血小板模拟粒子中含有网织血小板模拟粒子。
  12. 一种血液分析仪用的质控物或校准物，其特征在于：含有权利要求10所述的网织红细胞模拟粒子和/或权利要求11所述的血小板模拟粒子。
  13. 根据权利要求12所述的质控物或校准物，其特征在于：还含有白细胞模拟粒子、红细胞模拟粒子和有核红细胞模拟粒子中的至少一种。
  14. 一种血液分析仪用的细胞模拟粒子，其特征在于：所述细胞模拟粒子为表面交联有至少一个蛋白荧光染料分子的哺乳动物无核红细胞。
  15. 根据权利要求14所述的细胞模拟粒子，其特征在于：所述哺乳动物无核红细胞的体积大小为60-120fL，优选为人源红细胞、兔红细胞、牛红细胞、猪红细胞、马红细胞或豚鼠红细胞。
  16. 根据权利要求14所述的细胞模拟粒子，其特征在于：所述哺乳动物无核红细胞的体积大小为2-25fL，优选为山羊源红细胞或绵羊红细胞。
  17. 根据权利要求14所述的细胞模拟粒子，其特征在于：所述蛋白荧光染料分子具有可供活化的羧基，所述哺乳动物无核红细胞的细胞表面具有可供活化的氨基，所述交联为所述氨基和羧基通过N-羟基琥珀酰亚胺交联。
  18. 根据权利要求14所述的细胞模拟粒子，其特征在于：所述蛋白荧光染料为通式二、通式三、通式四和通式五所示结构的至少一种，
    Figure PCTCN2017071755-appb-100011
    通式二至通式五中，m为0、1、2或3，R1、R2各自独立地选自磺酸基、卤素原子或者氢原子；
    R3和R4各自独立地选自烷基或含羧基的烷基，并且，R3和R4中至少有一个为含羧基的烷基；
    R5、R6各自独立地选自磺酸基、卤素原子、烷基或者氢原子。
  19. 根据权利要求14所述的细胞模拟粒子，其特征在于：所述哺乳动物无核红细胞还经过球形化处理。
PCT/CN2017/071755 2017-01-05 2017-01-19 网织红细胞模拟粒子、血小板模拟粒子制备方法及质控物 WO2018126499A1 (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US16/476,104 US20190352609A1 (en) 2017-01-05 2017-01-19 Method for preparing reticulocyte simulating particles and platelet simulating particles, and reference control
CN202110162478.4A CN112986589B (zh) 2017-01-05 2017-01-19 网织红细胞模拟粒子、血小板模拟粒子制备方法及质控物
CN201780081863.8A CN110140051B (zh) 2017-01-05 2017-01-19 网织红细胞模拟粒子、血小板模拟粒子制备方法及质控物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2017070307 2017-01-05
CNPCT/CN2017/070307 2017-01-05

Publications (1)

Publication Number Publication Date
WO2018126499A1 true WO2018126499A1 (zh) 2018-07-12

Family

ID=62788991

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/071755 WO2018126499A1 (zh) 2017-01-05 2017-01-19 网织红细胞模拟粒子、血小板模拟粒子制备方法及质控物

Country Status (3)

Country Link
US (1) US20190352609A1 (zh)
CN (2) CN112986589B (zh)
WO (1) WO2018126499A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114608999B (zh) * 2022-03-10 2025-03-28 深圳市帝迈生物技术有限公司 红细胞模拟物粒子、其制备方法及含该红细胞模拟物粒子的质控物或校准物
CN114839011A (zh) * 2022-04-18 2022-08-02 桂林优利特医疗电子有限公司 一种荧光原理的网织红细胞质控物制备方法

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179398A (en) * 1977-03-21 1979-12-18 ICN Medical Laboratories, Inc. Platelet control composition
US4264470A (en) * 1979-05-07 1981-04-28 Coulter Electronics, Inc. Selecting goat erythrocytes to simulate human platelets in hematologic reference controls
US20050227359A1 (en) * 2004-04-07 2005-10-13 Beckman Coulter, Inc. Reference control containing a nucleated red blood cell component
CN1891230A (zh) * 2005-07-04 2007-01-10 深圳迈瑞生物医疗电子股份有限公司 血小板模拟物及其制备方法
CN101231243A (zh) * 2007-01-24 2008-07-30 深圳迈瑞生物医疗电子股份有限公司 网织红细胞检测试剂及检测方法
CN101236158A (zh) * 2007-01-29 2008-08-06 深圳迈瑞生物医疗电子股份有限公司 网织红细胞检测方法及检测装置
CN101750476A (zh) * 2008-12-08 2010-06-23 深圳迈瑞生物医疗电子股份有限公司 血液分析试剂及其使用方法
CN101881778A (zh) * 2009-05-06 2010-11-10 深圳迈瑞生物医疗电子股份有限公司 网织红细胞模拟物及其制备方法
CN102115456A (zh) * 2009-12-30 2011-07-06 深圳迈瑞生物医疗电子股份有限公司 花菁类化合物,包含所述化合物的组合物及其在细胞检测中的用途
CN102177437A (zh) * 2008-08-13 2011-09-07 贝克曼考尔特公司 用于逐一细胞分析的参考对照

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4436821A (en) * 1982-04-12 1984-03-13 Streck Laboratories, Inc. Simulated human platelets from red blood cells
US5008201A (en) * 1990-05-24 1991-04-16 Streck Laboratories, Inc. Simulated human platelets from red blood cells
AU3633000A (en) * 1999-03-26 2000-10-16 Human Genome Sciences, Inc. Neutrokine-alpha binding proteins and methods based thereon
US6960652B2 (en) * 1999-03-30 2005-11-01 Board Of Regents, The University Of Texas System Compositions and methods for modifying toxic effects of proteinaceous compounds
EP1169449A2 (en) * 1999-04-14 2002-01-09 Arbor Vita Corporation Clasp-2 transmembrane proteins
US7195919B2 (en) * 2003-12-19 2007-03-27 Beckman Coulter, Inc. Hematology controls for reticulocytes and nucleated red blood cells
US7541190B2 (en) * 2005-02-07 2009-06-02 Beckman Coulter, Inc. Method of measurement of cellular hemoglobin
US7531357B2 (en) * 2005-04-04 2009-05-12 Bio-Rad Laboratories, Inc. Preparation of platelet analogs
EP1744145B1 (en) * 2005-07-12 2015-09-09 Sysmex Corporation Standard material for particle analyzer
US8669106B2 (en) * 2006-10-18 2014-03-11 Arteriocyte Inc. Erythrocytes differentiated in vitro from nanofiber expanded CD133+ cells
MX2010003328A (es) * 2007-09-25 2010-08-16 Pastoral Greenhouse Gas Res Lt Peptidos y polipeptidos permeabilizantes celulares para celulas microbianas.
CN101561443B (zh) * 2008-04-15 2013-08-21 深圳迈瑞生物医疗电子股份有限公司 五分类白细胞模拟物粒子、其制备方法以及含该模拟粒子的质控物和校准物
US8211656B2 (en) * 2008-08-13 2012-07-03 The Invention Science Fund I, Llc Biological targeting compositions and methods of using the same
AU2009296397B2 (en) * 2008-09-26 2012-11-08 Ambrx Inc. Modified animal erythropoietin polypeptides and their uses
ES2637843T3 (es) * 2008-10-24 2017-10-17 Epicentre Technologies Corporation Composiciones de extremo del transposón y métodos para modificar ácidos nucleicos
CN101723874B (zh) * 2008-10-31 2013-09-11 深圳迈瑞生物医疗电子股份有限公司 花菁类化合物及其在生物样品染色中的用途
KR101674626B1 (ko) * 2009-04-17 2016-11-09 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 영양약학적 및 의약적 산물에 대한 품질 조절 생분석법
GB0911215D0 (en) * 2009-06-29 2009-08-12 Univ Erasmus Medical Ct Gamma globin therapy
US20120308985A1 (en) * 2011-04-21 2012-12-06 Streck, Inc. Immature Reticulocyte Fraction Reference Control and Related Methods
CN103454410B (zh) * 2012-05-30 2015-04-15 桂林优利特医疗电子有限公司 血液测试仪用生物安全质控物及其制备方法
CN104749144A (zh) * 2013-12-31 2015-07-01 深圳迈瑞生物医疗电子股份有限公司 血细胞检测试剂及血细胞处理方法和识别方法
CN105717312B (zh) * 2014-12-04 2018-07-06 深圳迈瑞生物医疗电子股份有限公司 一种红细胞模拟粒子、其制备方法以及含该模拟粒子的质控物或校准物

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179398A (en) * 1977-03-21 1979-12-18 ICN Medical Laboratories, Inc. Platelet control composition
US4264470A (en) * 1979-05-07 1981-04-28 Coulter Electronics, Inc. Selecting goat erythrocytes to simulate human platelets in hematologic reference controls
US20050227359A1 (en) * 2004-04-07 2005-10-13 Beckman Coulter, Inc. Reference control containing a nucleated red blood cell component
CN1891230A (zh) * 2005-07-04 2007-01-10 深圳迈瑞生物医疗电子股份有限公司 血小板模拟物及其制备方法
CN101231243A (zh) * 2007-01-24 2008-07-30 深圳迈瑞生物医疗电子股份有限公司 网织红细胞检测试剂及检测方法
CN101236158A (zh) * 2007-01-29 2008-08-06 深圳迈瑞生物医疗电子股份有限公司 网织红细胞检测方法及检测装置
CN102177437A (zh) * 2008-08-13 2011-09-07 贝克曼考尔特公司 用于逐一细胞分析的参考对照
CN101750476A (zh) * 2008-12-08 2010-06-23 深圳迈瑞生物医疗电子股份有限公司 血液分析试剂及其使用方法
CN101881778A (zh) * 2009-05-06 2010-11-10 深圳迈瑞生物医疗电子股份有限公司 网织红细胞模拟物及其制备方法
CN102115456A (zh) * 2009-12-30 2011-07-06 深圳迈瑞生物医疗电子股份有限公司 花菁类化合物,包含所述化合物的组合物及其在细胞检测中的用途

Also Published As

Publication number Publication date
CN110140051A (zh) 2019-08-16
US20190352609A1 (en) 2019-11-21
CN112986589A (zh) 2021-06-18
CN112986589B (zh) 2023-01-24
CN110140051B (zh) 2021-03-05

Similar Documents

Publication Publication Date Title
JP3391451B2 (ja) 白血球類縁体用の血液対照組成物，およびその調製方法および使用方法
CN107076766B (zh) 血液crp质控物及其质控方法
JP4549440B2 (ja) 基準対照血液および製法
JP3359921B2 (ja) 血液組成物用懸濁媒体及びその使用方法
JP2557837B2 (ja) 白血球の３つの母集団についての血液学規準コントロール流体懸濁物およびその製造方法
CN103336110B (zh) 一种全血质控物及其制备方法
CN101400996B (zh) 含有由无核血细胞制成的具核红细胞成分的基准对照组合物
US9995736B2 (en) Preparation and use of nucleated red blood cell simulating particles and hematology control mixtures
JPH0737978B2 (ja) 生育可能細胞の標識
JP2008026317A5 (zh)
US7195919B2 (en) Hematology controls for reticulocytes and nucleated red blood cells
JP4999681B2 (ja) 未成熟の顆粒球成分を含む血液学の参照対照
CN109459372B (zh) 有核红细胞模拟粒子及其制备方法与应用
CN112305232A (zh) 血液与特定蛋白的混合质控物及其质控方法
CN110987553B (zh) 一种红细胞处理试剂及其应用
WO2018126499A1 (zh) 网织红细胞模拟粒子、血小板模拟粒子制备方法及质控物
JP4873712B2 (ja) 有核赤血球の測定のためのリファレンスコントロールの使用方法
CN112639467B (zh) 血小板模拟粒子及其制备方法以及含该模拟粒子的质控物或校准物
JPH09274035A (ja) コントロール物質およびその染色方法
WO2004003568A1 (en) Hematology reference control
CN117347146A (zh) 一种用于血细胞分析仪的白细胞五分类质控品制备方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17890376

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17890376

Country of ref document: EP

Kind code of ref document: A1